ࡱ> rumnopqu Zbjbj]] M7f7fo%Y:nnvvvd V"d####R$6*7\680npppppp$} Jv8$3 D5l88nn#R$DDD8n#r#nD8nDD>4(J,Jޒ#`;r>Z0. < |ޒޒ1 v?f8z8D8 8Xf8f8f8@f8f8f88888 f8f8f8f8f8f8f8f8f8X 4:    SANUWAVE Health (SNWV-OTC)   Current Price (12/16/19)$0.16Valuation$0.60 OUTLOOK Managements comments, including those related to accelerating utilization, progressively improving reimbursement picture, growing clinician (including KOL) interest and initial positive provider feedback, are encouraging and suggests that demand-pull may not only already be present but also meaningfully benefitting these initial U.S. dermaPACE commercialization efforts. The steepening unit placement rates despite carrying just a skeleton crew of a direct sales force may suggest the same. But while anecdotal at this point and much too early for us to have any confidence in the validity of that supposition, an inability to reasonably discredit over the coming quarters would likely significantly bolster our confidence that clinical utility of dermaPACE, as opposed to more capitalistic influences, are driving interest in the product. Significant clinical utility could be a home run for SNWV. While our 2019 base case estimate of 75 systems remains constant, the recent addition of third-party distribution and positive (albeit perhaps largely anecdotal at this point) comments related to reimbursement, initial utilization and clinician feedback may be reflective of a market with greater and/or earlier appetite for adoption of dermaPACE than we had previously anticipated.  SUMMARY DATA 52-Week High$0.3152-Week Low$0.10One-Year Return (%)-47.69Beta-1.73Average Daily Volume (sh)228,860Shares Outstanding (mil)268Market Capitalization ($mil)$43Short Interest Ratio (days)N/AInstitutional Ownership (%)1Insider Ownership (%)38Annual Cash Dividend $0.00Dividend Yield (%) 0.005-Yr. Historical Growth Rates Sales (%)12.6 Earnings Per Share (%)N/A Dividend (%) N/AP/E using TTM EPSN/AP/E using 2019 EstimateN/AP/E using 2020 EstimateN/AZacks RankN/A Risk LevelHigh,Type of StockN/AIndustryMed Products  Q3 Results, Operational Update: U.S. Roll-Out May Be Stronger Than Previously Anticipated SANUWAVE (SNWV) reported financial results for their third quarter ending September 30th and provided a business update. As it relates to the financials, while revenue remains uninspiring, it has yet to reflect any substantive contribution from the U.S. dermaPACE business which represents the majority of the long-term upside potential in SNWVs revenue and equity value. Importantly, it appears that swift and critical progress continues to be made as it relates to putting the various pieces of the domestic dermaPACE roll out puzzle together. Given the number of moving parts, not insignificant regulatory and reimbursement challenges and SNWVs tight budget, we have been pleasantly surprised by the speed and apparent near error-free successes of their early U.S. commercialization strategy. Managements comments, including those related to accelerating utilization, progressively improving reimbursement picture, growing clinician (including KOL) interest and initial positive provider feedback, are encouraging and suggests that demand-pull may not only already be present but also meaningfully benefitting the initial U.S. dermaPACE commercialization efforts. The steepening unit placement rates despite carrying just a skeleton crew of a direct sales force may suggest the same. But while anecdotal at this point and much too early for us to have any confidence in the validity of that supposition, an inability to reasonably discredit over the coming quarters would likely significantly bolster our confidence that clinical utility of dermaPACE, as opposed to more capitalistic influences, are driving interest in the product. Significant clinical utility could be a home run for SNWV. As we discuss in our valuation section, below, we have made some slight yet meaningful updates to our installed base projections. While our 2019 base case estimate of 75 systems remains constant, the recent addition of third-party distribution and positive (albeit perhaps largely anecdotal at this point) comments related to reimbursement, initial utilization and clinician feedback may be reflective of a market with greater and/or earlier appetite for adoption of dermaPACE than we had previously anticipated. Our projected base case installed base has moved from 188 in 2020 to 263, from 281 in 2021 to 394 and from 360 to 504 in 2022. Financials Q3 revenue was $198k ($16k U.S., $182k OUS), down 67% yoy, down 38% from Q219 and barely one-half of our $396k estimate. Revenue through the first nine months was $693k, $167k, or 24% of which relates to sales in the U.S. YTD revenue is down 50%, from $1.4M through the first nine months of 2018. We note, however, that $435k, or 62% of the yoy YTD decrease relates to lower licensing fees in the current period. Licensing fees mostly relate to upfront (or otherwise lumpy) JV / distribution agreement receipts which are typically amortized to revenue over several quarters (and are not necessarily reflective of historical or projected operational performance). Q3U19 U.S. sales were just $16k, accounting for 8% of total revenue. $148k, or 89% of total U.S. revenue through the first three quarters of 2019, came from product sales just better than flat from $141k in U.S. product sales in the comparable prior-year period. With the installed base and number of clinicians trained on dermaPACE continuing to grow (and largely tracking managements guidance), utilization-related revenue now begun, positive reimbursement-related comments from management and expansion of the sales force and support infrastructure, we should see U.S. revenue begin to significantly accelerate. Approximately 200 clinicians had been trained on dermaPACE as of early November with another ~100 potentially learning the system by year-end. Clinician training is a necessary prerequisite to utilization and with 200 or more now versed on dermaPACE, we expect to see procedural volume and related billings and collections meaningfully increase. SNWV noted that more than 1,500 treatments had been performed and that they have had at least some success with insurance billing and claims. As of the end of Q319, 58 dermaPACE systems had been placed and (as of SNWVs Q3 earnings call in mid-November) 85 devices were anticipated to be in place by the close of November. SNWV continues to guide for 110 placements by year-end 2019 and for another 300 units to be in the field by the close of 2020. SNWV is now supplementing their direct sales force with third-party domestic distribution including the Ametus Group (with ~50 sales reps dedicated to the wound care space), which was brought on in November to facilitate increasing the device placement rate. Meanwhile, international sales were $182k in Q3 and $526k through the first nine months of 2019 while down 69% and 57% from the respective prior-year periods, the majority of the decreases relate to lower licensing fees in the current year. As we noted in a prior recent update, the distribution license agreements had not worked out as planned. MundiMed defaulted on their JV agreement with SNWV (for commercialization in Brazil) which was followed by Johnfk Medical Inc. (covering Taiwan, Singapore, Malaysia, Brunie, Cambodia, Myanmar, Laos, Indonesia, Thailand, Philippines and Vietnam) bowing out and defaulting on their agreement earlier this year. Per management, these and others like it, were expected to bring in potentially many millions of dollars in license fees and sales-related revenues and reduce the companys reliance on external capital to fund operations. However, given recent history, we think theres enough writing on the wall to suggest these types of agreements were either too early, poorly crafted or otherwise highly susceptible to failure. That prompted us to subsequently remove all assumed contribution from these agreements from our model. However, in November of this year SNWV announced a new JV agreement that is expected to pay them $600k cash, including $500k upfront at closing (management anticipates that to happen this month) and $100k upon ANVISA (Brazilian regulatory) approval of dermaPACE (which is currently anticipated in Q3 2020). If and when the JV generates revenue and related income from commercialization of dermaPACE in Brazil, profits will be shared equally between SNWV and their partner, IDIC Group (located in Sao Paulo, Brazil). Per SNWVs November 7th PR announcing the deal, completion of the Medical Device Single Audit Program (MDSAP), which was announced in late-October, is expected to help facilitate faster ANVISA approval. As we have detailed in prior reports, given the high prevalence of diabetes, lack of sufficient and cost-effective options for treating DFUs in that country and other characteristics that potentially make that region of the world particularly receptive to dermaPACE adoption and utilization, SNWVs continued pursuit of that market is encouraging. However, given SNWVs historic lack of significant success in monetizing these types of agreements, we are taking a more cautious approach to modeling this IDIC deal. We currently apply a 50% risk discount to projected financial contribution from this JV agreement which will be adjusted accordingly over time. And while licensing revenue accounted for the majority of the YTD yoy decrease in international revenue, OUS product sales have also been disappointing. International product sales fell $86k, or 37%, for the quarter and by $266k, or 47%, YTD, as compared to the comparable prior-year periods. While approximately $113k of the decrease in international sales (in Q3 and YTD19) relates to credits to Johnfk Medical (for equipment returns), there is clearly a lack of significant traction in the OUS business as a whole. SNWV recently brought in Alira Health to lead its European commercial efforts. And, we reiterate that recent expansion of SNWVs OUS footprint, expanding label from orthopedics-only to, more recently, include wound treatment in several territories and new distributor relationships are all potential catalysts that could have a positive impact on international revenue growth going forward. Certainly, FDA clearance, while largely meaningless from an OUS regulatory standpoint, can act as a proxy stamp of approval and prove an important and influential marketing message and help drive adoption. New clinical studies have also recently commenced, positive results of which could also aid in adoption and utilization. Among these are a dose-optimization study in Poland (as well as a U.S.-based perfusion study), which commenced in April 2019 and is expected to complete in early 2020. We should provide some context, however, as while we have been disappointed by the lack of consistent growth in international sales, we have always viewed the U.S. market as representing the vast majority of the commercial opportunity for dermaPACE. Management has indicated that the OUS business is (or at least has been in the past) profitable (in at least some countries) and that they believe it will grow. But OUS product sales have all but stalled and the international growth that was supposed to materialize years ago, didnt. While we do believe that there are reasonable reasons why OUS could pick up, given the developing U.S. opportunity (particularly following the update by NGS) and the resources (capital, time, leadership, etc) required to take advantage of it, we wonder if another serious strategic review of OUS operations is warranted. Cash balance was $403k at Q3 quarter-end. Cash used in operating activities was $1.3M and $4.7M ($2.2M and $5.9M ex-changes in working capital), compared to $673k and $2.3M ($1.0M and $3.5M) in the prior year periods. Management is guiding for monthly cash burn of ~$275k - $350k per month through the end of 2019. U.S. roll-out underway, comments are encouraging SNWV noted that they had 58 (up from 35 in August 2019) units placed in the U.S. at the end of Q3 and are shooting for 110 by the end of the year. Also, as of November ~200 users (up from ~116 in August) had been trained and certified to use dermaPACE and over 1,500 treatments performed on more than 200 (up from 130 in August) patients. They continue to expect to have 300 clinicians trained by year-end. As a reminder, SNWV places the devices for free and generates revenue when they are used which means it is critical that not only are devices placed, but that users are trained. Management noted that their main focus for 2019 has been on steepening the placement rate, while a more determined focus on driving utilization will happen in 2020 although the (favorable) NGS coding change, effective July 1, 2019, likely resulted in procedural volume beginning slightly sooner than expected. A CPT III tracking code became effective January 1, 2019. Clinicians will use this to submit for reimbursement (which they may or may not receive) and most payers will use it to monitor usage and for making policy, reimbursement and rate decisions (this is not as applicable to NGS as reimbursement should eventually be relatively seamless). As we have noted in prior updates, novel medical devices, such as dermaPACE often initially go to market in the U.S. sans-dedicated Medicare reimbursement. While we think that providers (perhaps, particularly influential KOLs) may have some success billing under this CPT III, we expect spotty reimbursement, at best, initially or at least until there is more usage data and perhaps, until following conclusion of supportive post-approval clinical utility and pharmacoeconomic studies. Eventual issuance of a CPT I code will likely be the goal, although that could be a years-long process and will undoubtedly require sufficient usage and economic data. SNWV mentioned that they have brought on consultants to help with their initial reimbursement strategy which will include picking certain regional payers and engaging with an evidence-based approach. Initial discussions with private insurers and MACs (i.e. regional Medicare) are underway which presumably helped facilitate the favorable change by NGS. We will continue to be eager to hear updates about the outcome of discussions with payers. As it relates to NGS, given that reimbursement claims will be individually reviewed to determine medical necessity, payment is not guaranteed. But we expect it should provide much more certainty than if the procedure was considered not medically necessary. And while, individually reviewed to determine medical necessity may mean that most or all initial claims are looked through with a fine toothed comb, we think it is reasonable to believe that as each provider builds trust with a history of valid claims that it will speed and ease the billing and review process and reduce risk of claim denials. Assuming that proves to be true, it will directly benefit procedural revenue and, given its validation of the economics of dermaPACE DFU treatment in the U.S., should almost certainly benefit adoption as well. SNWV has indicated that they will conduct an initial pharmacoeconomic study and that results will be used to help support their case to these regional payers. Importantly, a manuscript of the two pivotal (initial and supplemental) studies used as primary support for SNWVs application seeking FDA clearance of dermaPACE was published in the peer-reviewed Journal of Wound Care in December 2018. This is a significant event in our opinion, particularly in the context of communicating the benefits and utility of dermaPACE in treating DFUs at the clinician level. Other post-marketing studies, aimed at clinician adoption and utilization, are also planned in the U.S. In fact, a skin perfusion study, being conducted in New Jersey and California, commenced in April 2019. The study will evaluate the effects of their dermaPACE technology on local skin perfusion (blood flow) and its effect on healing DFUs. Additional studies, aimed at supporting the U.S. roll-out, are expected to happen in the near-term. These are topics that we will be eager to hear updates on given their potential outsized influence on whether a provider chooses to use, or a payor chooses to reimburse for, a particular modality or therapy. SNWVs initial commercialization territories in the U.S., which they chose due to their potential receptiveness to adoption and use of dermaPACE (under a CPT III code), are Texas, California, North and South Carolina, Pennsylvania and Illinois (these are the initial territories and are in addition to the 10 NGS states). The criteria under which these areas were chosen includes population density, presence of doctors with high volume of DFU patients and payors that have shown to be more amenable to reimbursing for novel technologies. Ametus was brought on in November 2019 to supplement SNWVs direct sales efforts. Ametus has ~50 reps dedicated to the wound care space with a presence in the U.S. Midwest, Texas and the West coast. Management noted that their U.S. roll-out strategy has Ametus initially focusing on NGS territories including those in Illinois, Minnesota and Wisconsin and subsequently moving to the western portion of the country. Meanwhile, SNWVs direct sales team will focus on NGSs northeastern coverage including New York and parts of New England. Management indicated on their recent earnings calls that initial feedback from U.S. clinicians has been positive. Among the feedback were comments from doctors of great results with using dermaPACE for chronic wounds, that safety of the device was noteworthy, plans to use dermaPACE for DFUs in conjunction with other therapies and use of dermaPACE when other therapies have failed. Valuation We approach modeling U.S. revenue based on unit placements. Our model incorporates three cases; conservative, base and liberal which are based on assumed margin (to SNWV), market opportunity, unit placements rate and number of treatments per console. We incorporate the following assumptions (all of which are subject to updating); Unit placements and utilization model: Installed base: we have made some slight yet meaningful updates to our installed base projections. While our 2019 base case estimate of 75 systems remains constant, the recent addition of third-party distribution and positive (albeit perhaps largely anecdotal at this point) comments related to reimbursement, initial utilization and clinician feedback may be reflective of a market with greater and/or earlier appetite for adoption of dermaPACE than we had previously anticipated. Our projected base case installed base has moved from 188 in 2020 to 263, from 281 in 2021 to 394 and from 360 to 504 in 2022. Utilization: on the low end (i.e. conservative), we assume one patient treated per (business) day per every four consoles (which implies initially, 75% of placed units are idle) and an average of 6 treatments per patient (equal to ~0.5 patients per console per month) on the high end (i.e. liberal), we assume one patient treated per (business) day per very two consoles (which implies initially, 50% of placed units are idle) and an average of 6 treatments per patient (equal to ~1 patient per console per month) base case is the average of the two Margin per treatment to SNWV: $100 liberal, $75 base, $50 conservative  Based on our belief that the early years of U.S. commercialization will be based on picking their spots based on hospitals, regional payers, wound centers and clinics as well as KOLs where reimbursement may be most favorable, we think the unit placement model may be most appropriate as a guide. This is also the reason why we do not extend this model past the year 2022. The updates to our installed base projections resulted in estimated U.S. revenue increasing from $4.3M (previously) in 2020 to $5.4M (currently), from $15.9M in 2021 to $16.4M and from $24.6M in 2022 to $25.8M. Meanwhile, we have OUS revenue rangebound between ~$1M and $1.5M each year from 2020 through 2022. We reiterate that our model is subjecting to updating. It will almost certainly change based on when there is more definitive information to make more informed judgments about inputs. And while we assume conservative, base and liberal cases, our inputs for each should not be interpreted to mean that, for example, margin cannot significantly exceed $100 per treatment. Valuation We value SNWV at 9x forward sales, which we think fairly reflects the potential high-growth opportunity, particularly in the U.S. We note our P/S multiple was increased from 7.5x to reflect the risk reduction and potential for accelerated time to cash-flow break even as a result of the NGS coding update and, most recently from 8.5x to reflect additional progress with the U.S. roll-out (as well as what appears to be incremental favorable market and reimbursement developments). With the updates to our model, we have SNWV generating approximately $17.7M in revenue in 2021 which values the company at approximately $160M or $0.60/share. (While our estimated fair value increased by almost 9% on a market capitalization basis from our August update, our target price fell from $0.75 as a result of the increase in outstanding shares).  FINANCIAL MODEL SANUWAVE Health, Inc.   APPENDIX Major Regional CMS Contractor Coverage Update Should Benefit Adoption of dermaPACE While we have made some downward revisions to our OUS sales, with SNWVs mid-August announcement that Medicare regional contractor, National Government Services, Inc. (NGS), updated coverage guidance for two specific codes that will cover the use of dermaPACE for the treatment of DFUs (applicable to certain conditions), we are more encouraged than ever by the domestic opportunity. Specifically, as it relates to NGSs update, per SNWVs 8/14/19 PR, effective July 1, 2019, CPT codes 0512T and 0513T (Extracorporeal shockwave therapy for integumentary wound healing, high energy) have been reclassified from Group 1 (i.e. not medically necessary) to CPT 3 (i.e. individually reviewed to determine medical necessity). NGSs updated coverage guidance is available  HYPERLINK "https://go.cms.gov/2L3cAgE" here (https://go.cms.gov/2L3cAgE). NGS administers benefits to 7M A/B Medicare members in 10 states; NY, ME, RI, VT, CT, NH, MA, MN, WI, and IL which, in aggregate (per SNWV, which cites the American Diabetes Association), represents 47.5M people including 5.8M with diabetes. SNWV estimates that more than 600k people fit the treatment profile for dermaPACE in these 10 states, representing what they calculate to be a total market opportunity of more than $1B. We had not anticipated this level of coverage nearly this soon, particularly for such a large covered-lives population. While NGS update does not guarantee every claim will be paid, it should provide much more certainty than if the procedure was considered not medically necessary. SNWV management indicated on the Q2 call that as long as providers only use dermaPACE for its FDA indicated uses, providers should have success in receiving reimbursement under these codes. Per CMS.gov, these two codes are not currently listed in the Medicare fee schedule but instead are contractor priced (i.e. NGS, in this case). While we will not know how robust (i.e. average $ payment and proportion of valid claims that are paid ) NGS reimbursement will be, management noted that Medicare will pay $314 per procedure and, again, indicated that they expect most claims will be paid (without having doctors having to endure repeated denials and rebillings). As is commonplace, private payers, if they follow NGS lead (a topic which we will be eager to hear updates about), could be expected to pay a significantly higher rate than Medicare.   HISTORICAL ZACKS RECOMMENDATIONS  Source: Zacks Investment Research  DISCLOSURES The following disclosures relate to relationships between Zacks Small-Cap Research (Zacks SCR), a division of Zacks Investment Research (ZIR), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe. ANALYST DISCLOSURES I, Brian Marckx, CFA, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice. INVESTMENT BANKING AND FEES FOR SERVICES Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article. Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request. POLICY DISCLOSURES This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuers business. SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article. ADDITIONAL INFORMATION Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned. CANADIAN COVERAGE This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.           December 16, 2019 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 Zacks Small-Cap Research scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Sponsored Impartial - Comprehensive Sponsored Impartial - Comprehensive Q3 2019 Update: Commentary Suggests U.S. Roll-Out May Be Stronger Than Previously Anticipated We value SNWV at 9x forward sales, reflecting high-growth opportunity in the U.S. 2021 sales est of $17.7M values SNWV at ~$160M, or ~$0.60/share. (While fair value est. increased by ~9% on a mrkt cap basis, our target price fell from $0.75 as a result of the increase in outstanding shares). ZACKS ESTIMATES Revenue (in 000s of $) Q1Q2Q3Q4Year(Mar)(Jun)(Sep)(Dec)(Dec)2018344 A 453 A 596 A 457 A 1,850 A2019178 A 317 A 198 A 889 E 1,582 E2020    6,734 E2021    17,769 E Earnings per Share Q1Q2Q3Q4Year(Mar)(Jun)(Sep)(Dec)(Dec)2018-$0.04 A -$0.02 A -$0.01 A -$0.01 A -$0.08 A 2019-$0.01 A -$0.02 A -$0.01 A -$0.01 E -$0.05 E 2020    -$0.03 E 2021    -$0.02 E  Zacks Projected EPS Growth Rate - Next 5 Years %N/A  Zacks Investment Research Page  PAGE 2 scr.zacks.com Copyright  DATE \@ "yyyy" \* MERGEFORMAT 2019, Zacks Investment Research. All Rights Reserved.  Zacks Investment Research Page  PAGE 2 scr.zacks.com Copyright  DATE \@ "yyyy" \* MERGEFORMAT 2019, Zacks Investment Research. All Rights Reserved.  Zacks Investment Research Page  PAGE 5  HYPERLINK "http://www.zacks.com" scr.zacks.com Copyright  DATE \@ "yyyy" \* MERGEFORMAT 2019, Zacks Investment Research. All Rights Reserved.   '()*+,-./01234λ榦榻ubuuuuYYAYYY/jh9(hq5OJQJUmHnHtHuhq5OJQJ%jhq5OJQJUmHnHuhq5B*OJQJph hY^h.z5B*OJQJphh.z5B*OJQJphh.z(hY^h.zB*OJQJmHnHphu$hY^h.z5B*CJ(OJQJph/jhY^h.z5CJ@OJQJUmHnHu1jhY^h.zB*OJQJUmHnHphu  '()+,niiigdqykd$$Ifl_0Z t04 layt05A $Ifgd.z $Ifgd.zgd.z ,-./02345678QWXb $Ifgd-Rkd$$Ifl#0Z N b t4 layt- $$Ifa$gd  $IfgdZ'gdq45678GHIJLNOQTUVWXbeghijqr      zzzk[hD%hq5CJOJQJaJh*h;/CJOJQJaJh;/h;/CJOJQJaJh2uyCJOJQJ\^JaJ#h;/h;/CJOJQJ\^JaJh5CJOJQJhq5CJOJQJhqhCJOJQJhWCJOJQJhCPCJOJQJh@CJOJQJhqCJOJQJhq5OJQJ#bhijr $U&#$/IfgdWgdqRkd$$Ifl#0Z N b t4 layt- $$Ifa$gd- u`$$~&`#$/Ifa$gdV*f$~&`#$/IfgdV*fgdq B & gdqfkdl$$IflQ  t04 layt-  !"%&'CDGHIdehij hHxE5CJOJQJhV*f5CJOJQJhqB*phhqhq5CJOJQJS 8OkdO$$Ifl0 H 4 layt-$$~&`#$/Ifa$gdV*f$~&`#$/IfgdV*fOkd$$Ifl0 H 4 layt- 8Okd $$Ifl0 H 4 layt-$$~&`#$/Ifa$gdV*f$~&`#$/IfgdV*fOkd$$Ifl0 H 4 layt- "&8Okd$$Ifl0 H 4 layt-$$~&`#$/Ifa$gdV*f$~&`#$/IfgdV*fOkdl$$Ifl0 H 4 layt-&'DHIei8Okd$$Ifl0 H 4 layt-$$~&`#$/Ifa$gdV*f$~&`#$/IfgdV*fOkd*$$Ifl0 H 4 layt-ij8OkdG$$Ifl0 H 4 layt-$$~&`#$/Ifa$gdV*f$~&`#$/IfgdV*fOkd$$Ifl0 H 4 layt-8Okd$$Ifl0 H 4 layt-$$~&`#$/Ifa$gdV*f$~&`#$/IfgdV*fOkd$$Ifl0 H 4 layt-8Okd$$Ifl0 H 4 layt-$$~&`#$/Ifa$gdV*f$~&`#$/IfgdV*fOkdd$$Ifl0 H 4 layt-8Okd$$Ifl0 H 4 layt-$$~&`#$/Ifa$gdV*f$~&`#$/IfgdV*fOkd"$$Ifl0 H 4 layt-./234FGJKLMNOaefst~ɾ饜hq5OJQJjhqUmHnHuhh)5CJOJQJhq5CJOJQJ)jhq5CJOJQJUmHnHuhV25CJOJQJhq5CJOJQJhV*f5CJOJQJ=/34GK8Okd?$$Ifl0 H 4 layt-$$~&`#$/Ifa$gdV*f$~&`#$/IfgdV*fOkd$$Ifl0 H 4 layt-KLMNOae8Okd$$Ifl0 H 4 layt-$$~&`#$/Ifa$gd-$~&`#$/Ifgd-Okd$$Ifl0 H 4 layt-ef~8Okd $$Ifle0 H 4 layt-$$~&`#$/Ifa$gd-$~&`#$/Ifgd-Okd\ $$Ifl80 H 4 layt-8Okdy $$Ifl0 H 4 layt-$$~&`#$/Ifa$gd-$~&`#$/Ifgd-Okd $$Ifl0 H 4 layt-8/h^hgdqOkd7 $$Ifl0 H 4 layt-$$~&`#$/Ifa$gd-$~&`#$/Ifgd-Okd $$Ifl0 H 4 layt-PJkd $$Ifl)0\  4 la yt-Jkd $$Ifl0\  4 la yt- $$Ifa$gdh) $If^gdh)PGBGgdqh^hgdqJkd $$Ifl0\  4 la yt- $$Ifa$gd- $If^gd-Jkd^ $$Ifl0\  4 la yt-    kl  7$8$H$^gd]5h^hgd`gdqh^hgdq     !./07=BKMNS]^ijμmm\\\ h Z6CJOJQJ]^JaJ&h Zh{6CJOJQJ]^JaJ&h Zh6CJOJQJ]^JaJ#h Zhx>*CJOJQJ^JaJ)h Zhx5>*CJOJQJ\^JaJ#h%5>*CJOJQJ\^JaJ,h85>*B*CJOJQJ\^JaJph$@a jhW h`UmHnHuhq5OJQJ$jklrt{  (68?@AP\abftw}~òàÏ h ZhOWCJOJQJ^JaJ#h ZhgtCJH*OJQJ^JaJ h Zh ZCJOJQJ^JaJ h ZhgtCJOJQJ^JaJ)h Zhgt5>*CJOJQJ\^JaJ,h Zhx56CJOJQJ\]^JaJ7  *3DKZoy '+-O_abehmsͼͼ h ZhMCJOJQJ^JaJ h ZhOWCJOJQJ^JaJ h ZhQuCJOJQJ^JaJ h ZhpCJOJQJ^JaJ h ZhCJOJQJ^JaJC 278;?CFGK^doqst{|} *.9<@ALQfhimtͼͼ h ZhQCJOJQJ^JaJ h Zh CJOJQJ^JaJ h ZhbCJOJQJ^JaJ h ZhMCJOJQJ^JaJJt~  !)-56CPQYbdelmuvͼ h ZhCJOJQJ^JaJ h Zh;CJOJQJ^JaJ h ZhQCJOJQJ^JaJ h Zh CJOJQJ^JaJC &5FHNORg{ #$,1OU^` #*234=>?Z\)h Zh6CJOJQJ\]^JaJ)h Zh5>*CJOJQJ\^JaJ h ZhCJOJQJ^JaJN   ',13EHdių#h Zh ZCJOJQJ\^JaJ#h Zh+N4CJOJQJ\^JaJ&h Zh+N45CJOJQJ\^JaJ h ZhCJOJQJ^JaJ)h Zh6CJOJQJ\]^JaJ; VWde ""%%''h*i*- 7$8$H$^gdr 7$8$H$^gdY~{ 7$8$H$^gdNL 7$8$H$^gd+N4 7$8$H$^gd]5 7$8$H$^gd'BHIW^ksyz":MUVWYZ[^_hinsvwyɷɓ#h ZhY~{CJOJQJ\^JaJ#h Zh+N45CJOJQJ^JaJ#h Zhs5N5CJOJQJ^JaJ#h Zhs5NCJOJQJ\^JaJ#h Zh+N4CJOJQJ\^JaJ#h Zh)CJOJQJ\^JaJ:(DOTUcdej}JNloptɷɷ#h ZhaCJOJQJ\^JaJ#h ZhNLCJOJQJ\^JaJ#h ZhsCJOJQJ\^JaJ#h ZhY~{CJOJQJ\^JaJ#h Zhs5NCJOJQJ\^JaJA&+W[akl  " 0 4 A B D I x !!!!!K!O!U!i!y!!!!!!4"P"S"W"]"c"""""""""""""""""#h ZhNLCJOJQJ\^JaJ#h Zh ZCJOJQJ\^JaJ#h ZhaCJOJQJ\^JaJO""" ######0#7#O#U#V#W#X#[#^#_#{#############$$$$2$4$;$<$B$C$G$Q$T$\$d$f$g$p$v$$$$$$$$$$$%%%&%2%G%H%I%L%O%S%X%%%%%%%%%#h ZhY~{5CJOJQJ^JaJ#h ZhY~{CJOJQJ\^JaJ#h ZhaCJOJQJ\^JaJO%%%%%%%%%%% &&& &4&5&6&H&g&i&q&&&&&&&&&&&&&& ' '')'*','4'@'M'N'Q'S'b'''''''''( ('(1(2(](h(o((((((((((ɷ#h Zh 5CJOJQJ^JaJ#h Zh CJOJQJ\^JaJ#h ZhTCJOJQJ\^JaJ#h ZhY~{CJOJQJ\^JaJH(((((((((()))0)B)`)p){)))))))))))))) *8*D*O*e*f*g*h*i*j*l*u******************+ +$+,+-+0+;+G+N+O+[+\+۵#h Zhm:CJOJQJ\^JaJ&h Zh CJH*OJQJ\^JaJ#h ZhrCJOJQJ\^JaJ#h Zh CJOJQJ\^JaJG\++++++++++++++++++++,,,(,-,M,_,g,l,q,z,{,,,,,,,,,,,,,,,,,,---------(-)-A-L-X-Y-f-y---------------#h ZhqCJOJQJ\^JaJ#h Zhm:CJOJQJ\^JaJ#h ZhrCJOJQJ\^JaJO--//22556.7/757g799::>>@@ 7$8$H$^gdc 7$8$H$^gdx\J 7$8$H$^gd=B 7$8$H$^gd`e 7$8$H$^gds 7$8$H$^gdr---.(.*.1.9.C.W.d.e.y.z............/////\/f/g/q/v/w//////////////00K0M0}00000000000000000000000011K1M1k1p1}11111#h ZhsCJOJQJ\^JaJ#h ZhqCJOJQJ\^JaJV111111111111222222A2J2M2\2a2q2s2v2}2~222222222222222 3 3363<3H3m3w3x3y3{333333333333333333333 44444(4)4=4b4f44444444444444#h ZhsCJOJQJ\^JaJ^4444444445 5555#5)52595D5E5J5N5W5l5x555555555555555555555556666?6_6c6n66666666666ƴ#h Zh`eCJOJQJ\^JaJ#h Zh`e5CJOJQJ^JaJ#h Zh*CJOJQJ\^JaJ#h ZhsCJOJQJ\^JaJ@667.7/707274757:7E7K7a7e7f7g7n7w7ǵ|||gg|R@@#h Zh`CJOJQJ\^JaJ)h Zh=B56CJOJQJ\^JaJ)h Zh Z56CJOJQJ\^JaJ)h Zhx56CJOJQJ\^JaJ#h Zh)CJOJQJ\^JaJ#h ZhpCJOJQJ\^JaJ#h Zhr:CJOJQJ\^JaJ& *h Zh`eCJOJQJ\^JaJ#h Zh`eCJOJQJ\^JaJ#h ZhsCJOJQJ\^JaJw7z7|777777777777777778+848687888D8R8]8c88888888899999/94979[9\9]9^9`9l999999999999999:ɷɷɷɷɷɥ#h Zh9>{CJOJQJ\^JaJ#h Zh <CJOJQJ\^JaJ#h Zh`CJOJQJ\^JaJ#h Zh ZCJOJQJ\^JaJ#h ZhxCJOJQJ\^JaJA:::: :::#:(:4:::<:N:[:\:]:a:g:k:l:p:v:w:::::::::::::::;; ;.;2;:;X;^;h;;;;;;#h ZhcCJOJQJ\^JaJ#h ZhxCJOJQJ\^JaJ#h Zh/CJOJQJ\^JaJ#h Zh`CJOJQJ\^JaJ#h Zh <CJOJQJ\^JaJ#h Zh9>{CJOJQJ\^JaJ2;;;;;;;;;;;;;;<<!<,<.<7<G<M<N<O<[<\<b<f<x<<<<<<<<<<<<<===.=1=8=Y=[=\=b=e=g=l============>> >.>1>H>[>\>b>l>>>>>>>>>>>>>#h ZhcCJOJQJ\^JaJ#h ZhbCJOJQJ\^JaJV>>?.?1?H?[?\?b?l????????????????????@@ @'@.@I@S@[@\@b@m@q@r@}@~@@@@@@@@@@@@AA,A.A6A7A>A@AAAJApA۷ɥ#h ZhbCJOJQJ\^JaJ#h ZhL3NCJOJQJ\^JaJ#h Zh8S|CJOJQJ\^JaJ#h ZhlZCJOJQJ\^JaJ#h ZhcCJOJQJ\^JaJApArAAAAAAAAAAB.BqBrBvB~BBBBBBBBBBBBBBBBBBBBBCCCC$C*C-C.C2C=CPCWCaCeCvCwC{CCCCCCCCCC۷#h ZhL3NCJOJQJ\^JaJ#h Zh6wCJOJQJ\^JaJ#h ZhoCJOJQJ\^JaJ#h Zh9CJOJQJ\^JaJ#h ZhbCJOJQJ\^JaJ>@CCFFHHJJLLoNpNqN{N|N|O}OOOOObRdReRsR 7$8$H$^gdQ 7$8$H$^gdx\J 7$8$H$^gdcCCCCCD DDD*D.D4D{CJOJQJ\^JaJ#h Zh_CJOJQJ\^JaJ#h Zhx4CJOJQJ\^JaJ#h ZhcCJOJQJ\^JaJH2F5F=FAFFFPFSFTFZFaFlFnFrF}FFFFFFFFFFFFFFFGG!G.G/G=GLGOGYGZGaGgGnGoGsG~GGGGGGGGGGGGGGGGɷ#h Zh8S|CJOJQJ\^JaJ#h Zh`CJOJQJ\^JaJ#h Zh/CJOJQJ\^JaJ#h ZhcCJOJQJ\^JaJ#h Zh9>{CJOJQJ\^JaJ#h Zh"HCJOJQJ\^JaJ:GGGHHHHHH&H'H0H2H=HPH_HaH}HHHHHHHHHHHHHHHHHHHHIIIII I!I"I#I$I%I&I'I(I.I0I9I:IRIVI_I|IIIIIIIIIIIIIJ Jɷɷ#h Zh9>{CJOJQJ\^JaJ#h Zh6wCJOJQJ\^JaJ#h Zh"HCJOJQJ\^JaJ#h ZhcCJOJQJ\^JaJH J JJ(J0J5J;JCJNJdJeJtJJJJJJJJJJKK KKK0K5K:KQKdKxKyK}KKKKKKKKKKKKKKKKKKLL L LLLL+L,L-L.LFLyL|L}LLLLLLLLɷ#h ZhkCJOJQJ\^JaJ#h Zhv]CJOJQJ\^JaJ#h ZhCJOJQJ\^JaJ#h Zh9>{CJOJQJ\^JaJHLLLLLLLLLLLLLLLMMMMM'M)M:M=M?MEMJMSMXMgMxMMMMMMMMMMMMMMMMMNN NNNN'N)N5N6NSNXNɷ#h Zh"dJCJOJQJ\^JaJ#h Zh/CJOJQJ\^JaJ#h ZhUCJOJQJ\^JaJ#h ZhCJOJQJ\^JaJ#h Zhv]CJOJQJ\^JaJ#h ZhkCJOJQJ\^JaJ:XN\NnNoNpNqNzN{N|NNNNNNNNNNNNNNO O*O8ONOTOWO|O}OODztttettttttttttttttttttQ&h hQ5CJOJQJ\^JaJh:CJOJQJ\^JaJ#h hQCJOJQJ\^JaJ,h Zh"dJB*CJOJQJ\^JaJph`)h8S|h"dJ5>*CJOJQJ\^JaJ)h8S|h8S|5>*CJOJQJ\^JaJ&h Zh8S|5CJOJQJ\^JaJ#h ZhcCJOJQJ\^JaJ#h Zh"dJCJOJQJ\^JaJOOOOOOOOOOOOOOOPPP PP3P>PYPjPkPtPuPvPPPPPPPPPPPPPPPPPQ QQQ8QCQPQRQYQƵƣhNCJOJQJ\^JaJhCJOJQJ\^JaJ#h hQCJOJQJ\^JaJ h>*CJOJQJ\^JaJ&h hQ>*CJOJQJ\^JaJ#h,hQCJ OJQJ\^JaJ &h hQ5CJOJQJ\^JaJ4YQ[Q^Q_Q`QbQeQnQqQtQyQ~QQQQQQQQQQQQQQQQQRR?RCRDR\R]R^R`RaRbRcRdReRfRsRvR|R}RRRRRRRRRRRRRRRϽ#h.b]h;CJOJQJ\^JaJ#h.b]hPPCJOJQJ\^JaJ#h.b]hQCJOJQJ\^JaJ#h hQCJOJQJ\^JaJhNCJOJQJ\^JaJhCJOJQJ\^JaJ 7$8$H$^gd7$8$H$]^gdQ$7$8$H$^a$gdQ 7$8$H$^gdQ & F 7$8$H$gdQ 7$8$H$^gd^ & F 7$8$H$gdQTTTTTTTTTTTTTTUU6UEUKUVUaUcUfUgUvU|U}UUUUUUUUUVV6VEVKVLVMVPVQVUV_VcVsV~VVVǼۭ۞ۏhCJOJQJ\^JaJhNCJOJQJ\^JaJh^CJOJQJ\^JaJhwCJOJQJ\^JaJj& h9%h9%U&hQB*CJOJQJ\^JaJph$@a#h hQCJOJQJ\^JaJ#h^h^CJOJQJ\^JaJ2VVVVVVVVVVVVVVVW#W%W0W3WCWcWeWoWwWWWWWWWWWWWWWWW XX%X0X@X[XrXXXXXXXXXXXXXYYY𽽽#h h:CJOJQJ\^JaJhs>CJOJQJ\^JaJ#h hQCJOJQJ\^JaJ#h hCJOJQJ\^JaJhCJOJQJ\^JaJhNCJOJQJ\^JaJ<YYYYYYY Y#Y,Y:YYFYGYOYUYWY]YrYyYYYYYY"Z#Z6Z:Z?ZCZQZhZZZZZZZZZZZƷ{hCJOJQJ\^JaJh6wCJOJQJ\^JaJh[>CJOJQJ\^JaJhCJOJQJ\^JaJh+JCJOJQJ\^JaJhEKtCJOJQJ\^JaJ&h./hh5CJOJQJ\^JaJ,h hQB*CJOJQJ\^JaJph/T+YY\\]\^\_\`\a\b\c\d\e\f\g\h\i\j\k\l\m\n\o\p\q\t\^ 7$8$H$^gd p'^gdj^gda1ZZ [ [[[[![7[8[9[:[;[<[=[B[E[M[N[O[P[h[s[{[|[~[[[[[[[[[[[[[[[[[[\\\)\/\0\C\N\O\T\͵٩ّhCJOJQJaJh+JCJOJQJaJh:CJOJQJaJh./CJOJQJaJhCJOJQJaJh]CJOJQJaJh`CJOJQJaJhxGha1CJOJQJaJh CJOJQJaJh7 CJOJQJaJ4T\U\Y\[\\\]\^\_\`\a\b\c\d\e\f\g\h\i\j\k\l\m\n\o\p\q\r\s\t\{\\\\\\\\IJ{{{rii^hlhuOJQJhB5OJQJh 5OJQJh 5OJQJh"W5OJQJh"WOJQJjh"WUmHnHuhvcph p'CJOJQJaJ#h p'5>*CJOJQJ\^JaJh p'CJOJQJaJh0gCJOJQJaJh |CJOJQJaJh+JCJOJQJaJhCJOJQJaJ$t\\\\\\\\\\\][`\` b bccfff 7$8$H$^gd p' 7$8$H$`gd p' 7$8$H$^gd p' $^a$gdes $h^ha$gd0;ph^h\\\\\\\\\\\\\\\\\\\\\\\]]]] ]#]+]C]F]J]N]O]Z][]\]f]i]w]]]]]]]vvvvvvvvvvvvv#hoh p'5CJOJQJ^JaJ#hoh p'CJOJQJ\^JaJh(h p'5OJQJ\^Jh"W5OJQJjh"WUmHnHuh3Ch p'5CJOJQJaJh 5CJOJQJaJj#h9%h9%OJQJUh0;pOJQJhlhuOJQJ.]]]]]]]]] ^ ^ ^$^%^(^6^=^C^H^I^J^Z^^^f^s^^^^^^^^^^^^C_N_Z_[_]_f_k_p_s_y_z_________________` ` ` ` `2`3`4`5`2jVhoh p'CJOJQJU\^JaJ,jhoh p'CJOJQJU\^JaJ#hoh p'CJOJQJ\^JaJG5`9`:`;`<`C`V`Y`Z`[`\`_`f`x`z``````````````aaaaa!a"a'a(a/a?aCaDaLaMaOaRaZa[afaraxaaaaaaaaaaaaaaaaaaab b b3b9bAbCbJbо#hoh p'CJOJQJ\^JaJ,jhoh p'CJOJQJU\^JaJ0hoh p'0JB*CJOJQJ\^JaJphKJbYbZbfb{bbbbbbbbbbbbbbbbbcc'c2c9cBcCcWcZcbcfckclcpccccccccccccd dddCdGdKdZd^dfdodudvd~ddddddddddddddddddddde eeeee&e3e;eh p'CJOJQJ\^JaJ#hoh p'CJOJQJ\^JaJX;e?eCeZe[efemeeeeeeeeeeeeef f#f9f:f?fCfNfRfTfXfZfafbfffifoftfuf|f~ffffffffffffffffffٹhqOJQJj2hyh/!FOJQJUh`OJQJhh5OJQJh p'5OJQJjh p'UmHnHuh"W5OJQJjWhoh p'U#hoh p'CJOJQJ\^JaJ8ffffffffffffffffffffffffgd)<gdnPogdYbgdqgd`h^h hh^h`hgd p'h^hgd p'fffffffffffffffffffffffffffffGggggGhGiGjjjkjjGkSkGlGmGnnnnGooGpGqq6r7rGrNrGsGtuuuGuGvGwwνhCJOJQJ^JaJhqOJQJh)<5OJQJjh)<Uh)<OJQJhnPoOJQJhYbhYbOJQJhqOJQJh/!Fh/!FCJOJQJaJ@fffgggjjkjjSknnnoq6r7rNruuuwwgdZ^gd dd^gd ^gdm$dd^gdm$h^hgd)<wwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwxxxξΛ΍hwB*CJOJQJph$hhw5B*CJOJQJphhCP5B*CJOJQJphh@5B*CJOJQJphhw5B*CJOJQJphhwjhwUmHnHuh|jh|Uh"W5wwwwwwwwwwwwwwwwwwwwwwwwwwxx$a$$a$gd.zxxxxx#x0xAxCxDxExFxGxHxNxVx[xaxmxtxyxxxxxxxxxxxxxxϿwllllah.5OJQJ^Jhw6CJ]aJhUhw6B*phh3K'hw6B*phhw(h^nhw5B*CJOJQJaJph(hBhw5B*CJOJQJaJphhw5B*CJOJQJphhw5B*CJ(OJQJph(h}~%hw5B*CJOJQJaJphhw5CJOJQJ!xxxDxExFxHxxxxxxx/y0yZz[zkzlzuzzgdq(gd.z$a$ gd.z$P^P`a$gd.z ^`gd.z P^P`gd.zgd.z^gd.zxy yyy#y.y/y0y;yAyByKyLyMySy[y^yfyuyyyyyyyyyyyyyyyyyyyyyyyyYzZz[zhzkzlz¾hw5CJ OJQJhw5OJQJhhwCJaJh.h.CJaJh.CJaJhhCJaJhwh/hw5OJQJ^JhE$5OJQJ^JhW{45OJQJ^Jh{5OJQJ^Jh.h.5OJQJ^J0lzuz|z}z~zzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzŻŻŵūūššh]CJOJQJhCJOJQJ hCJh8{CJOJQJhCJOJQJhwCJOJQJ hwCJhw5CJOJQJhwCJOJQJhw5CJOJQJ=zzzzzzzzzzVkdN$$Ifl,ֈB < 64 layt- $$Ifa$gd- zzzzzzzzVJ> $$Ifa$gd $$Ifa$gdkdO$$Ifl,ֈB < 64 layt- $$Ifa$gd-zzzzzzzzzJkdmO$$Ifl,ֈB < 64 layt- $$Ifa$gd $$Ifa$gdz{{{{ { {{{{{{{{{{{ {!{#{'{+{,{/{0{1{4{7{8{:{;{<{={?{A{E{I{J{M{N{O{P{S{V{W{X{Y{g{l{n{o{Ҿ쾾hw5CJOJQJhw5CJOJQJh7hwCJOJQJhwCJOJQJ hwCJhTCCJOJQJhwCJOJQJh8{CJOJQJ hCJh]CJOJQJhCJOJQJhCJOJQJh9%CJOJQJ2z{{{{{#{'{+{JkdO$$Ifl,ֈB < 64 layt- $$Ifa$gd $$Ifa$gd+{/{7{8{={A{J>2 $$Ifa$gd- $$Ifa$gd-kdCP$$Ifl,ֈB < 64 layt- $$Ifa$gd $$Ifa$gdA{E{I{M{V{W{Y{l{JEEgdqkdP$$Ifl,ֈB < 64 layt- $$Ifa$gd- $$Ifa$gd-l{n{o{r{u{x{{{{{{RkdQ$$Iflֈq OH&vw4 layt- $$Ifa$gd-gdq o{r{u{x{{{}{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{| | | ||||| |!|"|#|2|6|;|<|=|>|M|P|Q|V|W|X|Y|g|h|l|q|r|{|ڶڶڶh9%CJOJQJh]CJOJQJhCJOJQJ hCJhCJOJQJhwCJOJQJ hwCJhw5CJOJQJH{{{{{{{{WG$$If]a$gdkdQ$$Iflֈq OH&vw4 layt- $$Ifa$gd-{{{{||||6|WG$$If]a$gdkd5R$$Iflֈq OH&vw4 layt- $$Ifa$gd6|Q|l|||||||WG$$If]a$gdkdR$$Iflֈq OH&vw4 layt- $$Ifa$gd{|}||||||||||||||||||||||||||||||||||||||| }}}}}}}}}}ҾҸҖҖh|hwhw5CJOJQJhw5CJOJQJh7hwCJOJQJhwCJOJQJ hwCJhUGCJOJQJhTCCJOJQJhwCJOJQJh]CJOJQJ hCJh9%CJOJQJhCJOJQJ1|||||||WG; $$Ifa$gd-$$If]a$gd-kd]S$$Iflֈq OH&vw4 layt- $$Ifa$gd|||||||}KF@$IfgdqkdS$$Iflֈq OH&vw4 layt- $$Ifa$gdG; $$Ifa$gd-}}}}}}}}}!}}`[YYYYgdqGkdT$$Ifl)0& v4 la$IfGkdT$$Ifl)0& v4 la $$Ifa$ } }!}.}P}W}b}d}g}i}j}p}q}r}s}{}}}}}}}}}}}}}}}}}}}}} ~ ~$~%~&~'~.~P~W~b~g~j~o~p~v~˿ˮ۪ۜۜ}˿j[Xhw5CJOJQJUh+N4CJOJQJmHnHujhwCJOJQJUhw!hw0JCJOJQJmHnHuhw0JCJOJQJjhw0JCJOJQJUhwCJOJQJhw5CJOJQJj5Uhw5CJOJQJU1}}$~%~'~~~*+-WXYZgdZv~w~x~y~{~}~~~~~~~~~~~~~~~~~~~~  *+,-.PWbgotu{|}~ԷԷŘhw0JCJOJQJj[hw5CJOJQJUh+N4CJOJQJmHnHujhwCJOJQJUhwhw5CJOJQJhwCJOJQJ!hw0JCJOJQJmHnHujhw0JCJOJQJU1  $%.PWXYZ²室h"Wh|h+N4CJOJQJmHnHujhwCJOJQJUhwCJOJQJhwh`hw0J5CJOJQJhw0J5CJOJQJ*j^h`hw5CJOJQJUhw5CJOJQJjhw5CJOJQJUF 0 0P&P1h:p05A/ =!z"z#$8% Dp= 0P&P1h/ =!z"v#$8% DpA 0P&P1h/ =!z"v#$8% P DpF 0 0P&P1h:p1/ =!z"z#$C% DpI 0 0P&P1h0:px= /!"8#z$z% DpF 0 0P&P1h:p_/ =!z"z#$8% Dp$$If!vh#vZ#v :V l_ t0,5Z5 4yt05Ah$$If!vh#vN #vb:V l# t,5N 5b4ayt-h$$If!vh#vN #vb:V l# t,5N 5b4ayt-$$If!vh#v:V lQ t054yt-]$$If!vh#v #v:V l,5 54yt-]$$If!vh#v #v:V l,5 54yt-]$$If!vh#v #v:V l,5 54yt-]$$If!vh#v #v:V l,5 54yt-]$$If!vh#v #v:V l,5 54yt-]$$If!vh#v #v:V l,5 54yt-]$$If!vh#v #v:V l,5 54yt-]$$If!vh#v #v:V l,5 54yt-]$$If!vh#v #v:V l,5 54yt-]$$If!vh#v #v:V l,5 54yt-]$$If!vh#v #v:V l,5 54yt-]$$If!vh#v #v:V l,5 54yt-]$$If!vh#v #v:V l,5 54yt-]$$If!vh#v #v:V l,5 54yt-]$$If!vh#v #v:V l,5 54yt-]$$If!vh#v #v:V l,5 54yt-]$$If!vh#v #v:V l,5 54yt-]$$If!vh#v #v:V l,5 54yt-]$$If!vh#v #v:V l,5 54yt-]$$If!vh#v #v:V l,5 54yt-]$$If!vh#v #v:V l8,5 54yt-]$$If!vh#v #v:V le,5 54yt-]$$If!vh#v #v:V l,5 54yt-]$$If!vh#v #v:V l,5 54yt-]$$If!vh#v #v:V l,5 54yt-]$$If!vh#v #v:V l,5 54yt-b$$If !vh#v\ #v :V l,5\ 5 4a yt-b$$If !vh#v\ #v :V l),5\ 5 4a yt-b$$If !vh#v\ #v :V l,5\ 5 4a yt-b$$If !vh#v\ #v :V l,5\ 5 4a yt-Dd %0  # A"'U|"!Ȧ Pj b@=U|"!Ȧ Pg] 3xl]g}Ob;qKi@TG{[I6EfKEit^B&1yh*`J4VHd@`"Ъ"-И6x\9\7M&$_sy?N%IrXY7%GJ_۔$=#I%]$|Cԥ5I-7-WuK[΍HJz$jF%t^,.]FdT½GkGoRRYծgd #KkY%<;#zJg*xFtWϹGw{Ɋ깺HVVoPvzj~$,!VaǷ?QgӆKt񢏋|W3ېzmM{%mI򐮉ot}H'c6=lmxf~s?HK~~!W3?xzU-+4?חܸ~!ijy6_}gb?Bg^[dL|5{XׂE N~\g -~*|ݩ/׫BGگ?C:>~׭2 .:xr=y$y t~ʹNJ?{^__ZV=a[vGQt?ݶg)/y{>[O'<^O43Ò 5LEq1ԇh,8jHJ6~Wʽ顦J}9F]kYO>Ǎ{{s$Sm~s}Nkg1Ʉc_q>aSI^8hOVMm:Fƒ]uea`uck}1 @_sIuY~xcڧx-KZz38[W쇇~:a>'T^R"?Hv~$oK>mn~j6l] #/ϩ2uE~J?y,?R~T <_h6-u~xۃp|A2 p܋Hhi`čΪx_ד"ߡ玕5m8l?#~-%&gsܴ73ܫQ#'dcSy@r `|Jeaym{ʸ];viݧTZG__23%㒻n%q߯p PVCUqCcIMփKt1|m/\- pat_SgTGN(H/d1:켘==VǕǴ>k>_ $ Z$ g`=֊1GՉc8sA8aX<[?xvZ% ?gN\$?xFm#|q`cXW䋁 _- ցܚc]k||@;h.W Eb\ϲ&b `Wu9ybҹAi߳29ճ&bgxV~pfsN?J֋˸eMú"?'|}XO?&bg}}3ŘuRmX/.z5!c ПO~,Xz1Ƴny>MJW쇟|~pfsN?8 ''tZiؾsS4X9ZϿv>]=~A5SmjbϏUhy$XG\apN;w 7ZI7niq뒕-RUP6[VcZ9n<+FmOv*=SI9Tk:w=Go[1'|r2ktKl^JW!20o~L2!٠FiqkpiOiXg-zZ9ưn>usa]FYTЃ9ưcgns`cXW7 q$ၭID}8Q3F{E{E/.&N;Ba]F9cj  r!ưn;Ba]ߊ`Q.A."q:VN;Ba]F^9UFlZqJQ:r oU .s6jxX1[(cXW'kG0ú"wcXWYz5i_S?׫C+mbi= =: e\1ޗՎT#a0܋k^޶]<׺(̵#~3:+AZ9!6ε$aOze 8`'NCN.7l ń/ gU^$U}mݍ/il~?gB)ߨt=8LN?|~7ػ[Lºϱ~cYwCYڴ)wxmOakasx 5knKK=Y{o]cKdnzhoSwaw}I8eNss`LF(h\ab )˺'1ۈN%m_e}ZסJU(-Ų몖!D;&%?T0Á_w ߓܪ <;!;`g]Q u<7Ec\pKOҞ:m.r;>*G`BVox\dpdZ)h]H;eJ-Ω5x <>m3l]_!~7aúb;5;桦k QRgtOK:UA{3I]%Uqخs*. sшDtE|;gݥIobu꾼1 0g;]'+Gi׶ߡ!F82V+3O1qՏ}Zl‘q$h]ztS*gkb1S}YM:QtOz}X;0S{UoQ|kc| X󳮘߀>{:fVq䓊s+-Èed~}DK*ñ|rxLfO=!y\2nĘIY7TͣFx-s*3a\cF:ʳI?q~*qs8srs= pd̈9ZWSOw mREBfɺ깊pͿ{NAՕ$˵nvgq;_; V7/=*!o}o ]Eq}%G{=7󸡃۫*6y*I2x)IE󸡃[UVp{%~#\XPB/y+rF$[tI]myx|L4gCH$TN=yf;Gva{%r}i`dWq+I8:$t_V:m_깊y! )02Kbny|Bq֩)uY;_h?cXH<6jsK^*}׷swF >{vˉ)$q3SY<2_"J b9.2Dd M 0  # A"k2;G ͂9-_xG2$b@=?2;G ͂9-_xp . 2x Gy{dɖla]z|lY1Ǝ @m" f162CDH$uˆAa$$!XH’=I !1dA}]zu5u+_wWUwuߞ( .fQ|² Eqh[b86my<~Vc ~\rl]\Ѿ\NgoBa?Ss k->廘'i7I˃mqcq{ˋ22Z2šXk6]o1C92\xpo0f(Hɳ=~\/D0RӾc깣T(@>x<+\Fns(%=6A}tee_B^v9x⪢Y\OZ܅Xn9#Rurx$R]^{kf]|ߋ{UvZth{zAǏw_TĽVή&WgUgTs=gg/ M˯.ٺ{!ϒW?U]:i|Q篭|D$m_Ǖ1G_eQ`mΤ.h {)CVϱm^g_fC]>8Nk=0 lw6+z:7z5U<߸yxwQ ׉.C{~}+Ĭ):9m QZl1Θq%}d9^|\ eRgl;'x"K䚫,#fV9q:W͋c1Ρ.c>+Ǯvc60޵JZL㏟s0sr3~yʴ}ݴDW c}9^[P'G^16XNs97i>Y2=tHI].3^ǼmDO>Duu&u21,vcE]/>-Ut9dݬc^momN|bT#f+k\~cBӚIڋdyGnD,cș_jUcǎܯx͹|p2o}a;uc~^7x6lZ}V$R]ʊJ?hlb\ywxLӁK.cF-2v+wr8p6=rSu9r\#-=T\ʡN\wB]/,3˱ŶxШ{IS[ᰭX'i+W_8>FrmEmP-^*p%iʡ.cWwC=&p iʡN|tvAqx/x#q1' lG\h9p 3pL.c0=1k\7nd㿑r|#+Y+0E^m7!u u/X58 9+>f4'TYa9c?=VW φق#=KqURâM 2~4QU_0דsލ󞳊uE`d{oX)?Gؼ&7ScF}9zD7=({N}-\M6*.uqWxGh)<T!^l)ulЍ(m+^L2˳6j,f.uu˾{}NcoS369ջ_X9\I3s{?;o%w^2Kuy};KX9q\sݍixn(ps'cCtlB; s:gTinݶ~mruu6uylcba&Ln.vZ(jVlM, pyJ6ͲߌD<Bu900{rN^H2<فnm 4+|1VȦֶyUۃ<\ߏE|D[TV'9׉ QZD9S eyk]ȐE-n2M.'>=o1qG]v#746wMO)<`c6?9Thʣ.|wO?):y|/Yal,KMsy,"MɆwlkЍb#Gjn\9mwP`eCsyHһMsM7 q}6[]\<04ePðl>џ]@K2c.|/.\)9^4ePðO=g)0zVCo0 0`ʠ.a >[x] F rY ÷&n뤩1G|^ݧ PC?p{n8O5Fz&gk۟` xdr}m]=YExԹKٷ&{m(ql/`}`Y+u UlG%ld]vb;ng>QaV oue^x~c3ġ)<G\cge8,rKoP)<a~ryJ|Ru6 o5nQdM>laS6u u7F\zY{A9geG]JҷOةUg:<$۾A'nxQp3|1.WʹU}m_ g!zS#1sawmGDEݏc{&{JsZ7W q=&ig5>2L#Gd2l;O͝#7Zk.-Vʡ.#xvDZNùܔC]N;wכ-- N+ePg ={1mᜭrlz |nʠ.!<m~:\~4ePW|~7缭pN7PcMxΪ7)<['.syݔC]-緻os282a{tVuSu9 } z{ܭ r|+d>\yݔA]w׋.ї8!=^kpc/ry.Eqq̊ʹeuGVK~t;sy}iq}\f$2ljBJ'\c3PQtK8~.1;N;Ὧ^cv:(s):NlK6D|Deav<#Iy{1,`:1GYza{P~)eS;+6znI2eSDVўyuꜣlGl|_oF`[Φ.MvNvu6ul=k`^؞Φ.-̱ο-~پ7{n;ٴmufu̶_H欜3cM1<9|W#u6u٦&2{r.H\͜mlG[C'ߋHm.o>Z |:\ |/`|4*1Hz:u-[ wG#Tq{Q!.sn-D̽_eiёu1dpn-eP'שmʰ3l[ùùia]{#9Rʡ._|np~-P1VFlQ8\_Ot4pp@ʡ.#K3ir؁5|ܫΥ<[ʡ.û0gcvS/?"M9p8: Qo\84P'M :G0mrԍ]^Jf3\QcO?zb.96P.r8W_ӯ#9.Rʡ.#~CW=B;&o):9O sceխo ο r*cc{!qǾJkR==\y{b2g61._Oz.T(4̵% DQ3Txp7i~]r8/˿w;-,#uB&(GI=&S;j#EE_nuG7WLfxN/'QeGhkpC vte1V4GnؿaFRuy O-_Eϫ3cpnf~KÏSY38GZ.&N^d#Xjouo*.?8rYYVޚo*9:~&_W篮sgo܋侏 uq_2: n:\n2_h_`-t[/L#M_[g_Mrۘ6fUZ]Qk#6y$Jy eu&uy6# f ֙<m$/ܐ(ΎR/ έ-l34_Àm=wҔC]GxwR-\ܵSH96K!טn1E"$^sFN9uy˶Y/#m"q)~noh3^íI#ǐ]ZT/:k_0TVӹ`h|K("l@'idܑu®v(f{Za[YS[Mky⾟k ~NMұwko2>ecÈuyYCwHuO֣}"9m'ϧe_P J힖e 2%FIˠogOlY Wde]W9uF(_-G]n,O-Tg)?keU].}z٪:uZ_OfʔU].{|p?Ô}Ӆu RVuc`xy6oov&#unu>dvzs6f/{? x^׬sۻ~ӝK3Ju`ޏ{-ǩfQ\~([x̍\r1(:i2l1n%<dBSû"n@hxp(қuHaĺc1}~HZu'?\>g. |7HZuݔǧy{#)\ng0A?x-!WV'7At[tg]BxXMU_ wBRR>y.Π߱x,0p::X]oa8?^?Bsί;~8A]oePt/":\G;nҗq:#CupV^ !/T ?Be QPU$ISgx^bly`-Ҕ!^2W4e|Eߒ Q7(4Yx Y2\gAa`a.O ᧉd0RgA3x$C3?^u1yI`iu }lX57"X:՜7RmL+v /gHWe;{t+IR6ۋM8_z8Ou{4˂ ,+6QKL00 iʤN&Lх(|;XT+eb" 4ou1yic$K nyg0iBޯ!MV7ȼw ,#im7IӼ 2*I4ouu.iyd VgV7ȼ_MbA[ ~%!"MV7g\" WX0A{qڈx)1c v9'syO5+8r{c1d%1bǘG\}P1M{k'ؿ |quLқXqZN*ig,c-j2)ρ6rL6V ~&+dSnrgrL6wN3YY}&LgrL6ܘl_ͤ3LV~ɦ>>M}& ~&+dSnv}z3ٔgpgrL6y3}&;s]qWW֫MoDq1A>Muf3ٔg~s&}}3\zA7Q )CB^ c!R6ۋ7׽m|6w9*~Ͳ|GӾ[Q~cN'h4򪅁o~򩓏;m%}#`nȩ8d..P'sp)6^XeX;/ߤO2ڨo}8rbSu9[m g4y9fSu9zܑ[;/ߤO9qɌ̓%M9pl%v>o|7Zuѭ=fNS8|w VIrc6~E{t~k^[A]-ҠuwzQm6:^9\ Pg ٿSϵayєA tm57ioӼVr .O9q(7,cO:V6n{zm1^K?t}=FL54iqby1H1ײODK|n{q] (c!rnTZ2t#i%Lg=u;n+o,ݾPmWV%{ȫOؙg1ǝǯ)-ۺeF~H&a2˳QK Y<  G]b{"yQʣ.'z;E:<}}7R7ӧScFUQO!S$0J/:F~Huu64Z1F~H&aH]jK;E G]ϮV W;E G]걝oƶb<:-æc19Ruy[sO8Mg(c}Ca#>,4g>ȿs$:}úx<\4?u.ÂW\Oط7k.înߦ,cofgyT{?۞^o 왹VmY%"M.gi;[Wuu9O͞_elXDqO,k4n$ZzY֌{ݿ#xfXkoH+k;7\%댑ɹ/{obΌw?׮c-󬛜~;~&︓z}c(?"]v\{ɸ;˛O ~n7^X-lXR\_[ҧl<O(qe|׍۟~6Wr[NL۔zv|~~bj,~:xrW(2'V%_ŘR 䇐tӖ:u/]׋QgyXG% wteZ̯>bQnc8&nv;oO-v'x9F=(7f݉--nK4j݉-e-n8wNl؏rlq{Pl?n6۝^ܜv'xF[]Hq"FҥHQoާ-^݇GU1'cڿ9Oe[2O-v'xlq{PlQoܱN-n>v'xlq{PlQU6;cdۃb݉-k&[}TNlX7ؼ.Un wHⶌϧÈx,n OLQ']H1'Hi~?旲mgGxlʦN R$~Nld R$W~NldlnlnwbS' ٶ-v'6u&Avs:=H6fvNld{T6櫲݉Ml㤲=H6]es{#lQ'۟ 6fNldT6_̶M.@ĦNE> Do/N1Ҹ=HW%lnw:h(0@Khsb8s+zyRϱ48=CVX - !#S)-r} \!iֹ!X!xƋ xz:$HWt$v oCv د6_~me 46<tWʆzԧ=낆˛A X a>+%89tfEGQk>g 9 9/2(J߿ߗR+3R~L VDX98_ߐ2_į xBO@"Hg_cs¿_ޤlc@Z?&γ_RuO ċ=YD?}Voaॷ04&=) ".S#H Xz`\ ODy@$[o9l`=ؿb>h X1`z9_= Ȇz} A@{8Z9@^904?O+OQp?=`U?( H?!{>hB%OJuf|FkuBc & ]*:y?켰W;/ @ | 5~ؼ O>g6?)@E}?.q?F>>Vi=dXwC0@ vD( %$<ćbeP[(_bI |/ |+uaלTV`B'JL]Dr' /r;w ?/;Ayb ۻ/QO(sFۂUBlV J)ƐUwF} $C|hCގZ Jq^apF-1Az{\1~ (~t|7?ȝ7y!MK o% _㳃t+@$\H >8bR};6Bw)$W D( cy_" E (7Ay8Z|K^G'f.u_L u\h1Zk`d$y/ˆ"r"PpD_` "1H*%&\k4 $qL[j8=?]#}d)M.kꭩNrH}^輗n41+FTo݁ \WSncvdrر*S '[ !5+"  (ùGGh t_>'K?ua"=Z't \ .\kGd?B?,a헍HQO孂E>w4׍Jv@Λz~Q+I~)b_1@'5[a,Jᔼ, dtȵV ѝ\o V?ẐѮ<޼WGW. .F6ݪܪ9#&ãߩ݃Fz[dYa%/=0pY& wc_b~/TQKy(Fz#Ptht%&Y ]_y=^sG11ģg<% &Y 񺷣U[5fڒg!"Y&z޴*`5<8%I9WMx00Eh_"%O:N>ώSuGHDM"Rs ^[oRwM>4§?DlIz1u%5!^s=yU0=7s &bl5, འE教Ld)'j݆jM}n^v+GbGuXUɖw+WW fd`VYt3h=Z]~!* CZbq+OM^hX" £s;I 6 zoJf/̄C?EQ;89XF.X3EVqT hPeTb9O}9=CZ # j tOAG]jB+a{n%G+!=nn !R8\L'\u: Wfcsj5Ĕ'U X|E94=˙~*Dz~1YYLo'v0WAA_p)'u1$ Jr?Z0>bd0W?YVoOЗjbFv}G.kHrÁJ\30w&_idݸmptF_m yg7.޻ȴz_p/+GIc>Xzo"-l5UaYOPcۯ4};(Gx'[Xr~{bT!l73w=Pj/x@bI@wh.M1GRCeYy+(Mǣd;r;xnS<,Z<ٍJ`A;Br>xV2nGEn|Y[չ|חE Ӽ5bA]AN]':I@Zp~91)nDNdWAU?6SY+krI9/Pѝ}v<%63`s,|T)ߴڡ"-Kܳ&Z=ҢrG=.u9TX~9Kj9)u5ܷ#-ȇ3bȁ|:5h{۷۬J\xu#vHI -AI  4o朿>LbD4J IL /: :3(5yFsinNŪwr8&kY~/p|I;߉=ܱ ck԰8TL‚k[0'gB7>(6#lE.Q<"#t%&5WGe0ף;osh=IZi^'>랜j3KkaZWo|DHԺDSNpi#PZVQ)xX8ߟ ,K V }<d=*ֈ+˙= ޽y+SY[HC_Hf%o63D$k4<;Cjݹڕl<~DM'GC% 3cx0gʵ3&؂bgZ'Jv>xӳvVo+n_UN^cuSv:[0v:y)+ۂڗΑ3j(m5}G|H\#`/D椢o1fw4].jw}.6*v}ޮ#DjɎOba%7Lj#S^馫 h";2YaD |ʪ㦸+FG93y/ JGY.}_JpsPyGNXx mHLʽg*~I^܅ۼEy\*~iㆠWi?!6{(Z ١xx۔tqmw:-ÑX=ȽZ݁MZr. qU1V, *{;Q:Tp9%AG{L'A5q*vn!x'i.c{MNbZ>c脛Cw<ԉ]o]Qh錌R9%_ FYA@ CvZ!HrE69v_Vy8+äG&#^}mvD%xO\%#6+9qv8Gmʒ|9x_1w\ӐE[Q\Yj@f7 ^*\7eAOMv6B7D:&_+ iLLQx_y:2*<]}X1CM?ޣHO#0 $^AP|_ip{O$ˈYrƉƺm%R S\k!* t*h oYd6S/~:;&2 ޱا$k+*ټ!˞PѨ-ҙ1Aw|S^0P6 =ZͫYߖnF L LhgM\B0fskY=zV,ֲ-άl3fu#ZǮ3̟}[vWU)j5?-ŝlyi3x!E\{X48X׼ VW ʗ;"M e/75GaD,Px}[(qG]Utk3h> KǴUK^N4bgfK*E`/6m0r2'*-y}L3U Y%쟲8x/FѱWvzP`${]ϲoL rl۶J*d®_ S!-L"-Mڿ<ʍ; J4&Qc9:FE c-uFu?hl^($von^.ufR 3a xy'`q`?bG#dH"{Yvў% ⫬(qL#=0Bgʝ٘{RjkN}wHj9yU!1DR_؅v4z{]aq:;S\Mh_R{gKS3۰ 3HrťpT)V)^lCtG5ƻ$oӓߴJs )Ofqፓ?.h 6ߝf?#mP19n~J$AjtBJ~J0YZBTkVܷ `Nj&`q k]޸wg=}3acd+&q:Amύ]7a[r1GT/@}1fzr4LXRskP$َbR$@W}Q .lRGxllSY93g)LGV2 r#.KǏ9r{7ռJVPهx_]I+os-H`<"f9\\RcA lb4tGҁF@bTK˶3g]qr!ጾUCkZq}B#9zyt5X[>vxJYr9g9jҀfmV'^1h ݝɉN鹆+ŽB``!e@4էfCRjުR;AGTZMpf[Ȉ禱}q<-~:0z7oA'H(ZfO"KSҼjĉen%Qe"Ɨ\k⁲2.R̦F!co^L׬Rv`>{)ul8]cuo[۶[KcSi&׫Qxu۠ۓNձlcH{Ģ&SJ@}9C^0V8Ǩ9m};^Ex~jfY&Tɺ֩tZ-&񼻄,7$R^ֵǺBxei;bViC3;`+GKb_{gHuP|vg5j2(I3H:w \ -{aC}ߪU;jOu󻮦ɭY+0e-d4ܢ9*HĢn9cwMYv*@1!;spTb#nq{\:~xeF/ - =ʹezP.{8%j*١,Mӛ\b vxӿi$bH WͿxR GuEE~监<&7׈x9OAL  ɷdmGTRg)8f&u ̑`>7&+Mڄ4.xEQ.}%wۓ9kJ%&F*/w3O+Aҟw[챽0 )IO"!Qv"7;L& ]wZ|-EH]w{)ljD(L8a%5K2 sB/a)nT :tG5֟MIϓ&yeWnj%Cم9qd;gJ J C:C.aЭe{Şpm6˩ ,6-f{K}B7/BNү/#xk# Zni<}8nn0@spxDOGk1?Tx#;.G: vȤ H%lw9FaY,m&!'Yu^ݸhM8R^NHtI֫7Ոe3f V&k̰9G!u85o+|$#Ak#/Ga 9޶}-ݚrjńZ Z7Oۉl6~<*lpڷ̃U?c ߰]8RJ fk`N%.&Aë vpƥ&5k@* w*ބDžּ@kRanz!^SNf{&7]fL1~x,etkT0xD#r A`CVjB9:'[ GP鹜˦% +2Tx!^K<0S(icLwQL0zc!% "HmtoQ/)WG6AUO>z%{0v(ڏ.;-|e$.gKrsZR:H]I?LÌ\#/_NbnP=Bf GLF`@^o['@ P|@f#Q h ,yJkߜ-|0{ήqw'?FŽ @#7qw\Xi:}^`^SlV,?#yX{Oq1agX ,ȫyQ#)Р9%4Cٮchf:]+CArly7lOMf2Ko/kȋ&&ժ$GAojPW ~:8_03O -yjOK}|qXIR9XƎ)(;EKɃ>+UwD EwYo9Ґmquy⹚DNSG4Ŗ& r~q&I)Ƨ@h'A\cQ#E!%0_m yb43 vM91=(kqa։ Jy'מ(o* ZTjJ"[99^g\~5Eѐ2NE6~>ol(\O79sIPG.qx0R:JT\&.*AKQBj[^Jn@_?C@krN2?][}bSoYnZP̑ z+j>ڝ2 7SLX CN!'! w!ڋ;M;@FHA`pH&z)jjA6a q sbx>F d+,5Usli'RJՙauN}S~2BLo5N붽}•p/ lHd)KL)M[9/d蝩^O&# NѾ3pReK8c3x“k(0loւl,l*t;K Iq>$[Ӕv jA]5"/Ojp6 Iw'_+p…Fe:s~ksfn7^7GNºu}8+?V4|֋)4m^:>- 0%65CjOv1@ `Ls(Ȁ\_{E!iD2zzR?l\p4f9N! d6%tuU,Cs׉,\!|O{FR{jɰ]*߯$;,$̡L8̗XqhRfX8ɈC;!+τhQ$l9KzH ٷ~+OpHiR.&j}v{ &dkwxxvٷTF#L!lp_%$g!u]?Ia=߄J ,v6[{A` Mv2 q 4\Ʋf}As!%W-.xuFE]៯侓Rtve*в{t==!MpEstԾ_:Fe۶&P׋)těIT-[Jq2 g栭@\*{nsžID$~-''e!iKW7ac`3W >VqHzGzj/3ynR:0x۫wd~Uc2-:mKt\%4m=f*ROś@ʬE'97xe}! &#%m%vȻG\?vW0ZKMx]J J3: _sB<@X6_Z (ZWz[ryxA]ͥk/H}Yz] }zK--;i?MgP[ :#ו%1P=R͹,n+4|@#ZIrـU^u-3s-w(/RHD!Ü:lzuoi{j,od!{7He/чyboz?KWZ@M,姪}qDzrĺѽ#I ~P9.\\L>,623aJ219Pv%Cw,yK&1<},yNJ[e[.nvwzşi6hk2$,*v H/ /Pډ6 6j:7%;%:J X{(}a'L[.Yh73/)*_|3߉&5;D\;K=&e)9knpiU ( {jJ.[QFD>&-'h&<;ce,&o %kC#( q dX }AYķ>Y2at^<~G(i*}sk'8 ̒71pǏtUYg.1plx a=ZyhX^iǦ'j@ %na>9 {ϯ%)uebAAUҾN)w>J!kϞt"o׉d1"<+St_kaG(!+M.[LofN˹}L|`Ti;*cøyu۫i&,Xi5LLh<'&[8-h^/x3հ[G6RƸ+m{lwYwsj3WSnwσvٟNpK:ڱ'w!3LIbbڽ}B$tfTZ_0iӀIB|p3+ٓ #98>^_ih~󻾋+v+Nt"KE( ܳa w} 3<·둊{L93-NID) {N3:fr!Ss$ /+}ݘj}!.ljZ d_WW,B_a8DF扦  qޏ64`6G7±+bu>ƘsZjT߸` o4t\q)O9.Ol0[אrW>u`]4ΞfAȧqiڲ' +I N^i@p8(b ŀ߿Y}Qk =~ϩ_?bkt~[Yy ~}iƖg{3ya CDh]Ov[K_HMlڎr2ΦIٮ8:[.imO]ZNdՈ.`n#z[fOnɖ 1|DPbS'i.(jސ/bJ ~[ ::6ٲ4nQ&C=8La9n wOqMY*¸9q Kkopv]4*_zJ7/z*jz 0h>-yOb z,,Q Un.u S]1oMFa ah|2i9&~?r'DL0M q樛&?h)5sje $Rͭ fǯ].󆉇%de6L!* < le\S@gaibc|+`u:njއ_he>C`ϟ0c@}I׀i*C;.ռG<]#Ӝ.9E/^gus}RPRn5!1 w_3ۥ*01>Z2 %"(F-Q "NPr6@X)-P|H0A a>zh*w!vHXOLok`\i~XbI84['lpz4%Dq;~y J9 CPxOŽOhb)U A\:!_ kxb#6yx/J\a~)$.~J n1fN> Jhx}vy|kM $ #/p%*};kf9; R!lA@3<10R6$r܈:itoBI|Sѵ (:M "VI4)<m' @c Jb=zӭ&znG|qY+9ۋm*W:~) Q耸I+|>a "iD8lo?A'hdZ'$G2d έI'CF~U |qDFZxBq(䰃0$ &zL t+S\O@͸bw(4h7tB+~brjFu6&˟,}0ڞiO%јo6`)(M= b"@&bNŖͤ|l~wG:֔gΘp"d<>t{N|XJ\qv6"}ƒx4hhz'\r}Uʤ; >m7f:T~=)Y=#guL!6@/|:K<# *8zƓ1~q7e "TXMu5`F郖i̠  AX@Y1e۶=yA4%̎p?_nP.Y7X/>X΋ ݭ*7rQ';Uϒ_YFc!F^f&>3N7}:bEpA«Ka$@(-*U&ȜsX{f^հսLȶf2&.k<>XE2q}hYW} >#S tr2~Glus.TxUfQ|X F,ÜpffXq$!<^+78M'n3{^zEG4vIYek:mr}zoi3EA A:)LCɚ1}'-ћf^%Jmm2iXwK@/oWl^ai9Mat3CkC|-͌Y^v%3SXỉ+^Nͅw6 *T&;c׆V%W 'B[]էh3C&yx?  nPl!Uf (Mr{Ռ.VS ,mGi>yc4%]T,)J<쁎[֎Xt4,GmDIjiV_|bEˀ(:,0v̓!hj|sZ?y0kM#cozvYȉ2nA5~L|wqG [LIu(Rtesxƒj'a+ϝ%"̸ Q3xS`@XڒNe!-zN宙Tc,C, 3 ͷP̔>_BO3B P)S2ytt )Q EEV^U{Yb :?J$&n&xyv9fӾ)]F+n"Ն6.]t6UrCcC∝TaO@ߍ',jEto^zգK¡8T Pb7|wZIapFJj}r *ߕGsEqLG}O  MJu{qs#r)!+|RH㎻G߈p=A)㮜R(EbK/U5|Ʉ;Maʤdm&QJ<n(hxz9)oQJ=5^Fѱ,ԥ9{ʭd!F7"?&' k\6ai-_zJ}S fZPdM.4;T),%;i&Eq_U z-",)pp(b_o6XPZ U,x֗$Hښ&ɵn;=ys*OKGȷƒGpUפBvyyGk oSW/BEԼr!5 .Il濊Ir@~<ڕ8ԡ?wVUyz);RE5,r=n>*%e?wx w? =#-ѫ$߇+Zz2Ivlgy$O_oԿ~!zv.A #,ɬa{J_4+)D:> KϾ@#2'lZ:6rx-ZCP[}7sgg1E-v#^,4DYʯ,ٲ"kbSLT=>f^Og^pwjhP,0pL<^(pz70dugٔݫ_TrS?+\U/Oޛb.~B*RB_6O޼~@*@>V~njY]b5jւkTIU_t!>}܊I1+_N=MP8xc״@*GO)m5I2h]Fx%0Lܴ t%{Lw>MgP'k|e蓁t[0 sRl wǃ|d)O˩OI,*;3 ("D&,+,m ZaߖAjo㰐%4K'K_Y=`9E6?@ϟ)E6-inݤՏJw7^֣#j׭$ Cfpҕ'l»:sZ2_p{_j{ab,6HjAve˷`訛Ksb%=awn$CMP卡Pz)< e2U•-?9r5D 了O[[UhkKn^r󹕲b`biȠC\~=4;L7L@n_'uqi5.z@nMQt~}!;RN!w-?VN|mjetI*3/\?ߝIcMpʵ*DיyZƠW6{y/;uwzEhhؐ"m n7!nۄҀFWY+#{ɠ͊6 ?,Xg:c&B{ٺ-Q6k0U`g.Χ\(jMTmkM6AgİRf|(ZG >6i,Ϡ\uQ D){_7r5%E2-,6^XQ=(ZPF%>ԑ]ai?Ӣtq+e}aX 1d_},Cv !cK̍KW -ڟ+7!@OHs'gĈrl9M`3"_m E#ݟSa]r(3()%ĶwL&Wd%g`u ˵Et>?^J 3v~.If>_XYӥyRnZUyϪ}cf#h?w1[%`JItrT|\YDGq3;^6[_Tr]U-M~;f]㟱g0B1`;k9N] FH)_%Da&-(%-q?Lz@l}umqi;;7B5\Y^Tb~GFO]H |I`ˡ{?O, 7RYkܵ 19D-l4|3h[ w/W7ky~2Vש;wI9Y=>1<->Wzu+-YBҴ&^Zm2hbLDRG=DXd tX(iHso#3@`HMOMmwQRރƫ ZUl{bg_$6}/t$ e,JqN+%+1m^lt5Ԧ)癚[Nӧ*@UĭAʩ79aVdb<=un2G>cM2SjӟO{:Pѧ[LEqqޜWyHmΧ#,~oi>lɷ^!gC/c8nk0JZ`6μc/2TJF~^@ +lO+ݢiLΒ6_><ص8}Ӱ7|&ŷ9dÔEÙwߥ4fiv]m`yB -̷œGF5U7Xe9[1 ߓes'~HV2]=dc ù~0Z[o֝)m}P.*j9\V_smt_ۓ{ީo(YquM2S˔IdrF16*}!@;Ɏȫ EmӝQS[tGFWlݑ8/?JsGa*_{E=σX{\ |M#3+Ƶjt!WG{_}9.}ћ%:' dc~~b gkժKͦynJX[f9 L,\%^pbZM.Oabf̨OGB?loL=-1#LK&V$ws |Dҟw,cH[k PDG7  =R f4ҍ ]7]s@ьsVHc+ޘ @~qDIpmH>vjcςC8Ũdw27KբoFGm 7ܵn ;1}#rf\'rp>}iq 9mXuņUgKAX4j摌S^poh Vj'Wa6bk7C`_ګUxٿB{t5#_Bl\&^τRG\]h0Zt//m|:g"uXsĐM.ɛI 9^c/z6wv xe& K!@-=glt3t%8G\g|(q[tNp>Nq d_lT)DK=/T\ T)T󇴓/r m;w59X8=7kԮgLas13&#A5!_ZcʋKF̍>:^+{e-$|H$sَYY4[;,K/zL,2IV&#1X^ yy'=~=1,F -6QS%Wq9g[잏. _UPs )^xxtqG`Ɩ=XDL^y*4/3 %&=6!Yj.X_:~4({3n#e PsD ճ39,un:^+Qʨ쀾?O  ӌ6g2Gc¨ $ƚ܂Ee^p B'uġ%)nDeѯO9ϓ3wՇLcƼ✏ܕL{ij`*j^uP9 MQ8G Gzֹb}-y l`IՇ|)l0r pOH6)|GަlB3frƟ\l/cŽ|)nѷ?J,Y7lt&Ѥѯ@Sbps{w_5:tS>MRbi#9t0멡3Gs4Ͳj455Pt\5;[uh*oո~Vo)[mu, }=$oͺH81홱@k {j rHz#z!q(.Oc8=yG!NW9'dibK،6` fM/+|#AuN!4-a)_qf_r{JW5'Ǣ>1uAV>VLp1r˙(TéL˺F^e'3LjhXn^<H$Cb{*u: q~KoEX$-^Nw1Twgz/"θwG٣&1ǩP_E}+ F\B5jӛ CƛW$X‘2Vr H񟥊 ˳66EE#N21e NRtNu٘>H:89^=2u CUjm*6U?#\]dyo[t?+ nHx}]HE E3L}Zʇ NZ[܍c]zй҇{x )$~s'c0LL-&˼™~Q:n"f~)3sW _([fƛLQ۪1"2p~۞xk P{QUvXׯE-U/U'xӷʄdpqR&TKAw߬%I Qt;[-j"dgSąjG'o׀SʵGxA^Fy:&5WYs;63WRx EP]zW^?,wQhŒ d˺+%D@Udjw<<:l~\%U7)$lӺ١ hY5 7q?l:*dsY,&ƒ>}#i,o;! @|FUM\`u~TrH"%x5@P|]L}߰:`N.U$qp游fNe,^ľR7\GZ%lۢ#PD`7 ?TגCҲG3isbZ0Vk 77+i_cJXԢ;@9ZJ'} .enN) 6;wK@B ]<%9z@k461ꐐZD wwgl { @i#pj9RePH*d.4ĶL{`L\8e ?{u755iHY/L{NņwBFgwYnŲ#G \E\5p$iⲫ7B$-#$I 0*~/Y{^$?L2QeP6gYdF`9v4Xȵ #@N8*Wܰ2(dkqD\yN~l͇. jv^nL,bn t x.,#Őf_Th-OA%S{e6|WhjƝK0c| (׌>#K<;e^SlկxrY׾e4^#ҋ O'w*A~1 ]JLS8X*S&;zQ2zs E|"͚w&BvGEg3׭Be@P26HR`5IC3MyRHcԆ'{sS`G?xIj$-Pض 5H҇y^ y!FWžh .V%鬣vUj-:Vz T`t2x$dc{/wh 3W2_gl$@l-Nt?ӽjIS+M6-%]#lRӫo E_P_xmf?`溾i (M!MCGEmN:E{Ҧ59xӃד~EC o@Mu"]&^T(  {0!<]q?z'Z\-k^n=.žĈk#Hoyj`T-_E/oGHZ~7l(24΁p݃_Cs颳 TV&o.l࠘ !=#FT}<c xU3=JKxmR)}0\5=ǽ#޻;oTQdZf?)x 7u[Q'hH' )l|B8^&]aI- O"61p=}u9S[,igw)oasB۾lj^ymj}];\˻S[^sfTH1[y2uհ]9VKqk5ϖ5j E/ 7< k-aQWR4ԐŸ4w})  O¬yFryFDÃ1ۻ H7*:aTtL6ˆVZr>߲H7 (DFW{Nܜ4AVTARGBӢT98grR,-ۃmGbuV8Kf״L @T|}ŬGeɊ*KfP|iS(~bq̩Vm)^S\ 0CyeϻPHII mƣ][dR+3o:SLy2H5lV|?!cT2 iC TX?>I"5S'_aY\g~(2Wje #viDn&ԅZIwqZo*&t6'K51!t9c3LOj;d91movBTi0<K&sYzΠxe8gc &b\F`̝YV_04 u QE:\(EM@e 9;?]1ORT|}'Oj .(ώQDx!ZDU&Y)mV9 b &S Y< ؼކjpMH Jh8c fzn¯6jq3ENN[:5K>`$Pe7fqd'v1Ԕ\kV\LW Dgh..G 摼(HU_#ڞkX?>TW$ُ6uAzq&B%}uH>꜌p۔ֺMv2.ĥiO(hs!$q;7U&p(`|U._^t?;(k7t6j_m4dji,E m8m5Wc4*lY.ji6FGt# \r)eZ L](A_s,*Uip5$'jtk,  ~~)LIgw+zDb^5ZfH߻x(sa4(酞J_AÈf}cZ"K`A oFYI+p٠'E)1Lsb-spPm /1u p% [̗wwRָi2 gJ:T f <&:Be*\v8Xc-}b[T6x jSmsVR) ?eFkBnk>0iDgoȹdj r7\~1H 0K9\ 6ܐH`{;$,_6sn`g~F )_ۅNz U:deitBƍ˿5Gn̲'vLH%v (Cb9Z:0-/f 洡A c;,C7JIt.qUU.)mb[ +(\RYm6ƭq;SƗ)m]}}+ /$={Q9Eebm%֙{$,`'|lhO=#ž\V_*s?~Z^[$M j[>{ 1xl 'mkcQBoL<43xQl:RXYib&AE` Áʮ_I)>پIsfi=-@$HpT|H"X> /5j"*'&]EQի$lD}P4ΤG@7MܩF[gR*U?hiL_K@ cOBƧܷ,: ,(lv/ vP[18G ۋsdd$fOI80a|8Xi*oxT`*tea#='-=w#XaOtBZ8jxWmk}!mQ bD"џ)?_-꿨pc &E?DdxT܍+K?c(ja.|IhBt'_oޢѣdZ\#C ǣٷs[Y/dRmP䀝 'qK>)ȳJ&/iZS+զ ӈDt%VnG]wO@XnXMEIhDދo*HvRDD=SllsKpL(jE7wH6Y)g=CG_B\.:ٽFWD-GjZr|SLwk;u|UY6,^b+rσ> jY?j79NFpEݺ F~yή%\j8EZA6}ǟ~t(xIņ]'cf5#;ڡ.ۈU.*7DJ\YF 0 Dz6ƝPu2!ʏ.QW,܈ҥX:AٴԓQ)FQO^< 0vI+9<+ᆹ&Y,O1(a!8*קI<ܗ'@aY,$|2y4 >٤ >MyI&WnX 3մ^wp kss)AbJ`|#S3 Xq1s{_KئaNXMQ!Y"pUu]_;+H'jq*|R!T`!н/'ɾ,ڄDl*R@A~S:ÒV\E5@` !ݔะ8{;UI3Vl{-k ƜUk-G̗:5;:C_V4u73="XѫMЗo7'ChJzsޣ JTʬ;AމA :3zD]DD-:]>ze!o9ϳ9}p_su_\5mͱ3^p+ F`@(oi-bgl,.H̩?M@RMbEzÌM Ň߅y׋KB|-͟Wt=˺q!s-t?FG]Rma ~e}okEmVMDKOWpOH V@(٪#z1:qGw݅Cbc`Ӑg˗’zv>J^l;OY9Z#6).<ͳ*~ >|z>߫?('GIMѱU]+o*iV63֡ZuMfp7˙ ƹnExϘuyptg|5=my Z)ě]sͩ].qwF&N["Ө2,ji'E`[OL{;5zrioo¨bȒj0PB D=k~Ok`bb[] hwSW)}csOR1n;w~ԑ5;񸰇5`X*]^ìvisc0V{CGdҩЊgVѸ{\AVӠ=Q&4^xJ<>#EB-3^ABųLTt0 I\g =[fѣW \Y l'kX=n:n(y3^3 B+0O ^Bn1 *ˊ&E1ҬTC(B46r 䫻>|V"4)i|&Y\`bBd 1OM'6azloI2P/؀QK }qLa>Urz9 y79mSpi{Vʴmڠ;I'M9Nwq%9P-f h Bwr-ڹ rR\%V Ճ%z̹z\P"*QBkm_m绹QFʵ>Q7 :dv@(9fȨ݅%&PyH-e/&t{3Œft w&lleyB B}\mC7_қܬדGqd?D%aQ?FOވeWSM;mWOBj< ^L3 j-50M8 ϐzmW1苆=gXƷ<ԜqVW[fs'p2d9ONng`Sdb82Mn RFtv} |Wӗ'&vqk2 a1n#.k!Df‗.5ñi%0Ӻv,gao'Xz:j)\B-5PVjPh{ce Ev.t`$8^95oB[6@X~m.wBCjt^`8ICJm>ݎ~ktQdaL=SrWޢZ!r;"&lJp%5q{]nߛ$t5Kz?xЮДͅ `#yԲUrG~~lJ+B>h!g+uzd `d!Q]6Z<3*uvMoPn"):3abmMTƬ1A]_8l{ds=s`FԵ{H 9Z$3]} ՉIuo3ֺ:aCmEdjc[|Mmd/r"r i/%:VJf V2ք|0E*w<+#I*sd8Hq##;/:&͆d76b[$7Zxvezv0\4n2dv~8w&1 % mQ~Z'$i9"t+SPP+m͞É4o,gF7\9bl0}}W {)vdg7ƽsSvÛt=Z.`"ػpskWZ9L<]DbR}Do(`:ݺuђQU~MGIug.W`5ꔨ}ŰKð_N8#sC?έjx76Iz4JH8aӧцi|UxqNY{2*6b/pGsFDBSYNi4y#&ڜ ˃r>^[]sOBzcʓmG{#Q"8Q8 A7JbX$x׊NSfMbV Q r,QAE^|Iݚ!V) 䛊NBE**b \߅_VOc#=Ϩq)vg|A/Z㳒D"#q2nj3{7xeBX&IB g*9iۀ5 i s1Z񍎌u "!@6lK:NJOR*:}s@}r\~It2z>Qfoܖ)6&X;3y]C)^ ҃\(a݆9zMǙT'Svj#42 o(ڑk<-`\OA-!k3BJc3 \mHl|۴P_[zX]`3 ^$.v[GE b| uD&hN}iQ|`(Լ8ɢ? 54M!sw>$51|x/GQؽS nQw}@63\(Æ!=Wr$ͣ$b%,N+JuJ dbc^O܍IKYX` .:T?qʘmEx@]űb^=/q.`T?">m)ђeN燡!."e~q1zKoYYtbĠ:TODFUk0 C^N/=[F $lfeyBJAeqFBceܜ=Ĵ&h\aj'A0L'-ibrq(4̡ۈH~}YbV]qѳs{v׳K1YUa7`ucVOҤ63`(L Юܤ$:&dJbAt|Z!3W ngwA%g!X]:$&9u1+ږ}/0PĎYj.ޖ&{HsY[Zv^Ҙ#4՝ >5tƚUp7n347Ky5+ErÃY8e?i6>}c.V8n;}Z1h紐'e 0:~#ʕR7rӜ}ڃS`oj322rNn~g#jז+fl! "Y46?Jտҧ20~ޯW3vcj΄erC h&#ͪzly6Ǻ6ǻ ն|}?Ա~"O¦eo[{a5-=+~o9WYR&NyXI`cCE4c:j-q X/ z?YG>UEerapv)/mKr5+/# .~^=? +fbmTQ.%OqYU)yâ>涙_&rG[)Y k+Mo!%!4Z2_tAj(y͆1.?@/xyV?ݠ;G1>M{ޜzD@x'b#5NyP^F\pwbTC&\5[reZFF!.<[:(<nuY1C~Sq8}X"5=\NK 6i3mSNURTx8Gˡ43*wnUa;ى21 `q+.鹢ZK!HL:(S\ vƖƅy3Œ ֲ %`CKĦG@ ġn,rIDţ=M \?Y>-9B)yL9fR]ӛC$ESY&Y?nHS? ۫'8+Ve'-f&_8"$et%r Sy#Umo Ѹcl*P/3rCٱzM%e=[!ˆe /$9IXU%XC'So_L هК۬1ff?G4;9ʼn(lgꊪahXCG0Siv/eXx[Z 'ZY Ǜczdnt~їCi 6~a%;WUauh\\ wfb hi8l+ *_"փ^oL8l9*$ Au^+LS?.O^ {!LAqjd Ib"͊G6 & V<$;[n)஫=*-B)cHdl(Aqy&S+`8 Άmj; NJvcV1@Nޗt% 3z3nYbŚ757n=K?omv*QABbn3mn("E!ۛ#`rc̛^q)7pFut~NIOip8>nl4i,S<Mf To*Q tM9SV/cd2QV 57~r Hծ/ 3Kma/ +k;8FJ=S+LKK`/'.v:j6>\]%ѳ c3c'E~p`>W֥tC"RH(7ߝ\)LX10H(okpZZE5Vȥf+wb}ZYAE][?ҹz8 VcRpZ()ڈfd['L+*b2Z3".d *%e;C@컲L&m+oDڡ}L揰˺o?m\mwC?*KEAzO5%[y(] 0* bBӻq&Fc\+Z>-^ KOcۀuAD~,*c4v_ >_ =abUQ:9 nuAr:~)):j%(KG#Rߐ-r)n%ãvZ4bl7QdiR baf-=B"ۆKpgW\p|Fl-3 7t;<``lԷ/u") o*n.[B/>צ앁Q zN\15s(󸮲sKg>b1_ C&};!L|,YѦXO,գ&2J(Hx, M+!z+=p]ag=.^QB4RJvSH2OsY9ubLq^dz֪L:WRlqQRX3&iyOI? 2m4\M`5 R~WsC3Yv HhF~f٥&ol[/2^Ջ<Qߙ@jݸ:WQU.=a5!:%!XiWj /J.ųY/* yPb9_o\pCxޗ 6R"Kr?qhwO C(.íŬ6}F@kiWԩaWѵ nAY1=Lyץ]@d<垇qx[:sưpuђky+z/ٖ,Yu $ˁ ^dN.զW^)OQ`Zx*qu~8=l 3vؿO05a`;oBWW,S$ibtg=uj=Mp5XptQU"ZA<Ż՛.̭Kf=PTr0I2y$y.았T/ixjTOcZ}gT~FWuI_I1-47}ҡ'ǜX> p+8ӧ2q.v n/N3*MV~Ca"{h@Owjԥ>Ⱦ*}Ten|"a| \AK8Kfi 1,Mꁩ#3iY3ؒ*j -\e\p@$/[XrǼHg?̢t6+.K[R+ʏ5xs`5 J-3Y8.ܪ{aˉ(Z8,\x+*bt _!V\A\y%@pE]6n_f:% mRC@[j}(̝^ œɤEsp#|D`mqW-<K~ eȲN>c4ix.V"Ou] I'̜ɶu :*}>ᗛ4n<I^| *)Ga؂ZJkޒautFzHNK cZ-ٸ9 5>[_^ʴgQ/ +J7 ; ;aTtur nn#oGKkh{e jCJ'I9PB oƃ#-Z>\L9 S‚q{WSMU!dʒ2Y*QQ|(<3/!Y$#[>e#6c05Yiyo~?w߽s]kgHGw0MC_qfxszw3uWbGB~uetnT3^bfn+,¤Ư |zّoR;5j ~usɇɹVԪK>+O`C͗ ×-L[ޡVl﬽o4{إU?=49mZt|^h#!p.-4;nwoqAͮK{LpgY{>-n[Xՠe:OPmn\eHzn,;p# nwߠ)k7G2;Qzt} K9.][A_V~eO'4|jzdL ?jyC uVݿ̸=ɏ?㹀w[)zqO3>|L#ƾ7o_itɽi&K747¤ՙ>̓p#6YvvAkͿ督vӥCzV~vtI/+}$)+Uu9ԽIU^/hjf ly-oXx`rL?K)Nt?cݮ4cg_ e3Iu/_ϰ=q{ZmWo_nK{ڄ~:?;Z}ޏ_;ryg yA_z7a7c)nD4j8^0søk.̳?GߍbC3]׺HXrLI_ ^zT۹F1U=ij÷5Bo~Pvy\k2yk~Agt~>N3-;v\ɉx?8rߟ5{ͣN^^>ޅsV$O;2dx]~g%F֟7qECܜ`ЎE {p:U.t_i1/3}jbA9"_#s:d0!:Tk2)$b]͟oYN){ZoڥŃq^X?7uNw׾|ɮ t.]eL}xѯjXĦ,[V΋y&ύ_?lgV̍v2S i?`Ma yg u-Yrg`g y&8:^[3&8g~dh`MrhY`a7f=bgUZ!Ysݝ_ٳ_lZ_qntF̘=vcYfV(X}|TuCX oRyj]&=3]ɕi.C~4Q-+{өӹU?֩Q?s]|D-7[Xocv)]. 9/Lg Q~uG#_̯|ԔVԦ/JEvsXe9/s+&Nsvޱ9&+ZlۮqƑ.6Xpϫז}TgIf[r]cf{/:e{+g_h}E;:%m4}22=$vGмyq-$Ds˺>8?M,~ w[>C ܶ:q;mպo B^0<sSo-ٸlz+o nx E'aƞZxʵ`xe6~zMu\GEO{hzȯpE]_U[>{4om>)dl<}Z^K/OA?bʋy#?xxݱMOv~~wH!RiݯOf5B+u;ǒN[YXv>h!!sfF~"\6NȘti:ܯ+5;k.ubnj}&zߒЛ}'t+qH6DR'O2ξöݚ7OnU|LLBcʼnk7T#fQ<6u}m>vnkw" ţlG)a[Co; P_aΩv۱d3 u4 g gtZ/!,m>]v|n.Wn֠Fz%pc#BEmQu)qn tݻ{nqB@_"S|dUKp$SB*+9WXWEWW9W[R9~B6 } ?xVI/? P E2) +Ā=bD**2Q(<#iuH?S(pxxmk:\M}2<#{XLI%5maN#sXLIϩ mߗ|r8N&$Ց⼾@yFZkp8GL#jiX6Xp8'N&$|?kĹ;x:G#x:\rK{}(28?C䚄O>!}j-+G#P`u2&aEX?޶b:s8V'kW9_=m{xNG#`u2&.h(UIo>p8C䚄?{?`6T%VG#dظp߄m#Tl+j8MxG#P^Pd4Z $,/궭p>px\'ۛ#nG#( :r?g6_nﰊ+;Qaߞ{L~ip- wʕ{8-V X)Z$uaKp8 nN%`w4RDwm'EWU~pW㬰P(tjG{KnCMuv9f`%zs\Nı@ 㳊o^Fg.8_CTlU?MtQupBqz43?G#P16bj%wH '@bYc Y5Z$UXԳ#T…iVUF4:M!)D]eXk`5{x$g,[.[S:(r8r{t7>khܹ#NodLQ):-`L0gPԃ%qj?`<_MC.F%HW h!Ubk]5Go!)ǽ|paIcHluh.ZnPbrcItE=Pb#=xǻ !zyxc:Y8](Zý6\*EPYV zKcm:_ Vr@ `>p16Xa_HE|8_jz%Xg%kc'$`@lg j 뷆4q]!.׃?fI .{64T*nG3U E_Kq(ߑ op׽:¾_O;k M`3Зl?׿>t=X| r碵ES:] F֛m0@9FkoKޥu`J^/qOek?p7 ~ZWjP7R_j%5da}ҰD>$?M:Zz;wlӊyBNT8N~VEUЖ%s8o V'k28oG#drMBNCmkS^#GE䚄o8oB훐G#drMw /h0Uzxqrz 52=%L²/`vT=\=U̽]c[mVa|0?G# 0$N~`\j{AF}Um 7֌CenzS]ߒZӜ(}3{@g/Y}w)C],w?/WB=,n/R{_M2_xD{Du^K^]ږ=ްb-?SA9(lI\X٢~kr0$Hkq:uV@r3 %Cfo5X ȟ:*R" ]}}abLיab%euHB1Ϛ~N.$Ha3kyߓh˄k*T2Z׋*ybM?n55Ku3i<$l*rLUNwŶ*rR8Х5•&}/R$Xk ˍf?+J:I{}@1C>$Hf_Igh/@oAXk` it4RDw,ǸU4Px,ղF *[JY/W^,D@~ Կ D] S( %,Je^%+6ė )7 نJ| vl+z[(-Lu]3分$JQn3̄h\L&VRS^hW WŶnNwXå.PC-~+;GDtpW=Io™4hSGh2O) ,'.k*Ȏ|ak9h]*XvԸ|ih-ij)?M),?KXɁ _HhI1O~\kc˥:$r {ēNf:IK2jgB.m,(}D%}DY2Q2)p'{VFwu?,$!E*г r`WR~Tb s , Q95i7$A,=FL#w#K/>X {Ƈ bÁuhl0C g .KtmCtM ;`cq|{0Ӫ3Gh}NcPЃZxd{R.Ye5;GH[ldd 6xz/(84*m01ZC,=zl1)X>!@O"gdI"dp<35Ř!]3.䄟9;Mq bgZ@p䏫DW5.[}U} f{B̛pfNl[+A4u4q5'(oD@;_L&;ד.eLd ?``![.{ oQ$<*/_~ Ϩ% FZ2ϒxROgOR|c^X\,A,Cr>7bq s ]4qJZ[E %X9O=ERs\?R{"VGs&bdIN&RoD⡷˒A0螌AAY_aƥh̎i|}s(ücxCECqyU|eDȯ})7ݬ$K=Xuv|3I|%\<=O4 ZXmu-Y)uDk}KǙID+eI%Dq#3 CңwsGT0`>q- BaY7o`dA|_*>_\c$9C2!x)Ipa)#|@[Ife^H}K;J[R~hq::Aq)J# 5n@X[K|3G R;ST(B -o@'W=M+S?;YI=\Z$uwGCrt8,,ih J~qwo>YACcHv"7QV%1 Xlb3'JjRyQ"_i\9]oD(#*т;m<&hlyT1=m_FJXY_+CȅbA[<$% 5x@y&Ս1+ѷ u:G$Cv}ABm}opX/\ɬ0h&3o;^"Mj0'Â<?-xZ`}af .;l#e d, cll,57e[crlW%>Ոc10cx̯!P˜>|t1zj4!jQZh*z|̞C&PT.!Xp3#ZUMgyІ A: 1OQ(^Juƻrzpˋϕ3ҏhCSʧJOf2;Bπ 7 XPl4/L=H gھ9LՖ[35T^Y>Dedkɸێeˤ랴GLdKG6% Zhș>~}hKp%t I!\˛䎭3]IkB|c_!W, 5,WsQ|6<'{;MyHXo-Qr+?YUG?MIJc?93BBM%H'=M8,>\c>I{Am - 4q eڸFk$-o;V^ OZP)eqxİLϫb/sf^G%*Jj[2(;kW>)K6X cÑhɧ1e-=KYcnv}#>5եu&:M>. hkRh}Wicx4o ;=$ctm#x/Ydm^o3Wf0}Q惝+x6჆G;;8uvF;>MIY}\O&>">'HXoXUzމ׃aNrY߈OtGn%|<*tɖGg}d)Ws$dݕl=&}iU}f=}OL%g,d + )ζ: ĖNt0MHy`$R5(#xl6ܫTKIS#(7W* "wqt4ԤON!b!q9DwZB߃+kirgW4Xi']^' J컳h0Ѽ=rq,PM%W $Q-s=K FDBb'>&$t{MӾ0hF|62&@Å/AsJر0$!eKi@}O0'鰾h+d-Ci1<Е0#DЁd,[R:+\w9!텒!tP7w h|ڞs%q&'5O}JWӇòp gns!Rd|4}?kىZ$XKs'&kHtkprD=p'ʫ|HP.dD-Zio`h>y&^Opz憤媄 0w >uiX{.m@e i-\P*?$=,sd.#c0gioW&?[jK_^9([͹D! s'0%I:YOI.m/ m$UGQbujb քe]8z˚ Es Vd $+O Cߠ d^?1~~U]UݧŽ o7Ϙ?J]'H:Щ|G:uR@Mz o- ,ͯ?YfzGQ_K(fq}Is)p5i=m ܍ͣuʧ)^3/ {;WNtYS wU.bGM _P}̧+^7NdǍ{.ۺXq5l]@}L_Tk֧ͩ17g'i}+ΏV'Hlp_oVn}.F^LHA;Qڽ*JWs4Fnl2gup 8@Y>81rX`P@@`F\/(|s,̵ r- A v2$ Xh,.օd"!e\Kp %sl7 |~Lk ?n!bG EۡjC4W]dp .a,# s\Im%ú蕴.zȮC 8@KPOtfϋ=sy]zrY[p&F8.ݢ9N9bG[ \lﵾk []C}f\} lX~SM|n;7d]C.1oy58C!Ύ6v<_6nE/4ܱ[|wCqc?aIJ':|}_h{iooe 0yXXHxOr"_18 ,?q ?<,gSwuZNģ= btg9g{6u n`FL~&|΂Y[T]-|~ɋ)\LrŞ`O㪷zxc#<BWCܠ @,f<>x~!r'SMK\is{_֑V;K(WxFg])5(> _3 ]5i:j<&_{eN}G:pr4htb넼9}t0}%,>f{oNor>?owatJȼm|g-V%\' T<[{~<_p'<}D}*5bJnbk{#0i4s7G?i#UٷSj:so7ty%6#\K5NhAv̳a #xso@:/5Gvԍ77ˎMzV_~4vKH ű> 6 UmbyJ=${vvbef<1;U6p=k!&jlg쫐R<:[m^l-̍ygS8KA((:)qʅPʝvely(!?)?ࠃ1J$[{R| ؉b~ zf|&Jr|anpgv>xҼu[:k)>ke2Ʈ^b%6o!ɦj.zRM)z{b,Zs(<[UQsSVy|y=}uyYb:D9,~\б}v-}:k: O-H(x/GD+u?b0Gvi16 y/ Ҟ_| $iNHuvx`I/!3?LS 1_ O~Xf$/zx4<ΚHQC2B33zt4&v$obؖ&ܗlU]ڕt^כF޵o\<~'G4tp:|ihcQH[VKz7mføw&~R"Iw\m&oAO`CϻAvkqoK냖}byHo6E[[i6zdsJ9ِm(J"PGH4ڼWi(W.^oz3+ \|}tPn>>-Rj: hMVG+ kHGb3.\%' V0> CjÛ#OwN~Q+/6Oy-?/"|k_X5gw,?pqqI=Erz&o'=uY^ \'{0wU1TSh5%UPKVsJJ:>=VfDێ~nĖjvZbr|0zYCJgy۾zh{xE;ZI"yucͳUu5_iyDk@,WlS\З[ŕd}$.i->-Yqtvu_%mA(W )4H͓z>~lG};mkһd-6B9W*OezL{|}:-Ϥem?E!֔tpX~&DzA %v}ߏ?z6HGϔdzhƭ:- NhWn^ǢߕdoS8bwȎk׀zV~̻-6|5|}7{ܻ;>5/bgY,ϖ6[4bMacJk?\>}*:fCuNrC+҃{QW?& bOzx6k#l;ԛ%mn 0ޏ5nDk6v+F/HR2S6e~8r}|ޖb~ZF6TbVz٪~Bg獿+.~ 3 MuZ2{ծ5'hLXʭϷ" "xƲiZ$'_.頿vQz6om 87,iMt1Q NvGV`Tj:`ݩIyH-|x+{M/Op4?iI|r3GiV%\jm 1'\B|t̍⊡\Kjjs+p=t07 ,'ڟ .W[!C X?,cpX8,׉^r#ťcm>,@@ 8e`7awr0kg%/zhaM@@ [Lk B h2@>Z&˵)ӥ@R^{@ 2Y%\nm k@@ h}+ UTon%efj-(;t |C~> |6|vKr-!x4_kN7>1U|7֮-dr!'gﱅP˿ 痶s;!@@ kD&}<{)݂1עkaBo`@˂ |烯g'ktD>pT7Gyp| "0j;g6K-z[]%=?F?1b('Nap0s&{gD`FNQ 'r?rtɳ1zN`0e~;=[(8Nd%zoψ؟*\> Tz4v]`& ҝspy6\ԣ6VnwgƂoI}t=jP~xĞ"[JdLGicϝcKZ~/nn1i^xd]C|,J8=Lr焹ԃ|p>ċ"^ɵ1%A8>Nor߶O蔥:sOǦIʯtfCeZpm6׽Ǭgb,ҭeּ2}nwռY)+TM868Xi1q"3cUW[+UI}{ڬnqgkZ]1t|VО*rU#xyt?^UI3{!d֤CŸ .XTZdߏ|rmr*Kj[r_>wr:=MO(^~Q|.:+}۞hmtښp_r!Wx@ >ux}C@Qqto=v%+ @+IsҺVcLG'rl(nfݷ5\}ll~V5'̑]tRTZwɴy|0ʚl(G}HQ6kJ¿H[|`U[@(U^p׵^Wo߯7;K7q=! zm? RP;{/oXK?2w2zJ ] ny5˷\]^5矙vJjC6oh>Õ._z-[0='f՚es.Xz! .Us㟶 N9^Uذ vZYƟZ'0m}*v{9XEMiVR iNޖ2Mb~-n.q{^qN¼ MF106.ztFk CIAil#<̑Wn8Ny'IiRG46Ö$fGZtcm}n` 6@F%ȕ)mnD!Z/~ym$Yyp3;liad(|)1̸}j<\%v?_c:xˑ͚eڑ ^u4_s˯D\6ץs}:?swZ.w`r\5&2qs}ΣN[s]|p~xلLeZ˫?imgA7]k,O۸hD5DǷ1(G =lΕ7,Ft0%ߖ𩖋{N8bKy4)ٞ{E${IƦJ.sabǞoVִt;)ǰW|mq[( ǵv]}QF\['<)7 {!=F Cٻ>9ݗzOyXZ}Lڄ5#NQG;g6mMUYGj\GAvɇ+5b?l*j܏iu-? 0/o.[_Ӹ{|T?4F:_׌p%E$Ϡ>gvz4iO_xZ8OFB-oKs|iڵcOzi z}ܐou-}fE]lc{F2vAXRk[צYfqXKckL?&b޳GlOy@Lmsc,<k2#Axbt%cOدu}kv:6os^a'FyOI<_nY-lԌy]l b>xd`%bbHqreRXo;7moC8ѧmz.x |a;g]ou{?*0Rb?D烯#"pIjWL4_l_]J|;Um9NhH50|t ~o:<A|_KNytu~#\ӪoVpik}?{7GhSRs |4O꧷%jU t0㘡8mI}ώAyDH*5x⠃Vs[z'c<[p>lUH?VX^^l._/cǞ%INI|h vN.UԇG l)?q?{^ylm^MhΟZmv濯+X?lËĶv0CWUO|lOqLGٶ|2⻃]K7^?{g[~`I7շf#}"b>{X2~\ߙijV#i ޖ84}LWޑ<J9Kyc6Z?:'ot0Ꮯcmc\<-w˥f)G*dMXy|"ciòER\O?њݜ1x{.- fcj .sw+Xo}=Xեj}DWb;zz?>Rbiy'W9?5d^b8H- 5bse:ou{#hG\Kky7X|\rV^yjSOV"} 惧&_t_=mV߬_rR=۰\z>_]9G+ߩf\h-pDjI8Eӱ~z}锿w=y<ޏ ͷlnFn>tZOoΕv4K`pl24G]wU).gc5l;r9@,V!km zCϱ~]wV>&Btz6n|h≆y6[5k(~2?{ʼ)e^ {_cqˑ70v*]CNԎ1"8މy~D5~]yQoc>x/؎\B '6/znk$x?4@{:.3o&}Z6` .>7vY=DO|la>|f片`*o.Idmi{fU1皏d'FDx| zM׷vNraJƉrztztq8Xoݯ_1_?ىvQ*ؾE Y?eЊE<=-|y~,|)]]Pӟ'/G;;o9hy73$`~wrw+.k\p|eX-Gjˠ}׊ӤzzDxYt<CfZ9Z0|p޺_9y V xN5 mH!!K av;q{UsYo`MIm⵮6b_B>_o0N/wRY[ 퉯 {mk5kOz>] l{du?__л.c۔mv`kמk@_q?sL\N!F/Y5\_(HUto@p`_/O=msX@j]Ðga;q~z3Sz[ެv]vڣC/6Dx%YO_0bJJJK]gKȊқu񵟟{;fFO/Wx?i>:ݸþ=K-Gۣr{>7mw>7n=N;vnXvu-d }?YU/{"-:7h>cv֠),B;^޾_m^ޯyuJ ߷h{opדY#j{|Wh;Ais{_V\V˫?S sR{ Z1 "=+wv>Xr1 ȊENXrV~ūOAOzɴx?!?Bqxj1=k\A|[w\mnCx@{U^=|y"z°W?we:>{=~y?U޳ Q[0?;nh̶fs2߽X]ܮz^R.I~2XhJ+ q©=`6Am2b$t{׶[5K{.?q3+JG$jm_Mvؒ)vD ;rQ${|'25G{A^Zm._G%{pjwjC }/@x簴>qW½کq@F|:X;8 -=\7p#OQtv0|LBo|Y-RtiH.O~zl-t-hoV6t& APR@ /f5J}HҘ' 98ڞW7槿'n>W=$|'\-^tj&,Ø/rrE`V tyMuhJ.'DZ8ǰ ap8y-*E*?z~~-+Y~ֶ+z?z~J  UO< M" G@dpK%7x(/ G@d~f"hT),GLk c{WzmW: -ZTP[@1nZ&˵"B vq#& Xh,ldgm']Cr-lQL΄Nx-O@@ [:? W jUhM@ Xh,.Zτ@Lw@@`~2Y%ߚ@@9>Z&˵-k)!h,wLk {WbmW"CŊr-bs#h{؅@@V#e\Kx -<)UTo3 IA@ X(Lk NܹC@XTcBA /3{C净ZТN^ȿUJE 4k W*&˹ mMރж@@ PD&"mK~4ySj\6dzڀ@@k1YO,Ox tlJ骵pG׊g?5M]oyHtm|F[ϧ_l9YtMOi{crGa@@`"tʒNIkVbxZq@+-wa޹]ƦjdZza[9~;yzT[Yt @ ؝_i?~t 6`T2|1۵[BuOH|SF>Ň#tKoֿzx9ynh|z)}qn 2ȣփ-";wƩ"|0*l ;xzVV !tp*'W~14#:xJ< + W O75d~xw~>mֶ*gy/1qfnqv>=d]5tp D NM'ZX+6.4.6m߬m9R46Y ov|=]W`[YZ!tp*Uo< Tdt )B T "L 3vRŮ"#nTTRiG%jF%͐ԈQFIMcGKIef$wqŏ;k9^{syZ{=Q,pe}3nٶ'sMpƸzڵ/5t[>m?;]\xbZwZ"Y~5~~UYwUb3~SGM/6p>]?wf*^AyO.FC6Z-'F.a&: ,I ^\6Zq +1a&zIkjX }L^plp@ DHt2_%U o \,؆~E/?7wz%6O'l'D J])OsXҹ 2%ڡ@@ 05NcI.ތތ\ 4_'˱K_oG/ ,!SN{.%Gߗ( {:9dm\0ƽm1>߀ByH;X;/9 rq3HK2; @/߬[h+Gх;; L1K-J g ]@[ĀuEa|u!ⶠ"aʱK*-^:޺<M.(WNэ|ӐMo{eصT7sʌϷv=3C.tvO/ s|efܫݷw>ق܍Uw}2l~I{گ\Ҧ3Qgmt=S>i5.n!H?EkF|l>d^/o:#Wi &z]4_jz%fXlXHg+;z2f.v]rs]﫺d+M]4]=;eM>\pǥ~-_;|,o^O1fZMl+Y`v)UYnQT![5kV ډrNiKjDv9KyizOƆ䋡d6jp頶9ۆ|/6or/B>Gh7RcPJ{m9<矯-ѷA!q.mQ8'Gq]NLK|לM@/<G/d|FIB}BcIAv@tIo'Ihl8:4'A+3c3N Xgn67a~XVm]ڬsY^\-شZKKד26\I}8jc1ݠM7Vم~}׷am_W;5Al~x*\MmwUv^Y[lH?IsˑmFlL31-^*YNm݊Eh+}FW?\>NMwս xn"niZ~`,fփ1*C҉-*[ʇI;w]=hN|~,:ol+۷1_|*w뭻摎cuTݹ?獭d[o;Kr/ooՓ1H$c-&޸>:~%:ux*ɘ bžhh,gGkG߬h1ùGo33tfjK:3-Z}n䗍udf9h@AXl{$ixqm/6砋 Cl)Qh>ܳ-c|a.,Kc~Y̓}|~OI?3AK[܅bU:Բl+#Z\#lm, m()Y^nCfW\&Ѻ f#VG1-[Y>lY++qM^ 2}gW~c+_.Z1Ss~G(BN}voT9O'o&)ퟍ|@6]_3J0fa>Ey 6x <436sk6%ebESQ}$D].wqL]։ZhTw_ /?]o9(^^i|JyA!ts<ʾ~OmcPfm, tUL7?Vo˵Zu,ΨWHt"ng+̞vs "V{PbP`0_pbp}H桴 x<%s*\򏫸KV 'sb 駖֑VxF *\_z=|~suOisb;P܏fnV‡ܓkڞȖ[y\ +?6ݥع_w5 L6wFS_1_7˼[AW/[i%$$ iπz/MU?Tנ“փ].t=iu-g,ǹ~9>FŽMtzo|qGsVXq_Ȱ1j~Y_c:GXJzz3Nc,iohp%e9u1Eg`~]l[}Gq|Z_hȬ.i7,&QHnc%H>N+X ]q +R/5A(Tᄫؙ`'c.=2E3w(_TnFh|P!_{,{K[+*kU>pI h=ȡ{$vy= 6x,ǡMgI%ֱRd&iU5uS I1MįWΕxEm$7:dlycQglH|dHJ&09K48plF :/o}OKCjL4켂'HGX<æ{vGiŃHْT%&z݉XsN帼]Mx)9J$-dɖq R%@ƖذwG=s:SI6mt//'\.TrtH+=G!ʇF>w׃V)4켊ぇ+lp󄀵_b=#-<>ն;x`mIHtw͔5ke,CzC~C}Yr8Ҙ$t&`Ə8*ϓLf)Ni({uHEG~ZZX֏J$hD'{1W}$֕9侤RR9H 3?z0#s-WO$EW}>ΘcwN+ґ8G]wFKiy8giY0}ߍˑ臨kG*>왎&:Z?6x,|G߾Nϖa%wgŨs|=V nZ/(Ɖ?۝Ey<`Tn&,>~!=~Lz<.͡K,tS+uX5 K.wј^1[;v; 9kX ZJ2tqò7k̫s */wW.Ħ8G&x{h.4_Pv`[Hrt [@qZ]+aNDf =#;8Ocg>|A9`6?Ibsv1hqx &tmr2pyG/Sn\_z0Zy}iD9S󯋅EcI%OH}nd$#kEgͮ"ط, ]ڮt{>󍙳/6l]k5h5{d9`1f^:.%㿮&9ζ֮Q~)^3i3]#|Ī\ӫ]P\7>[[iփ!i̚1fSGQ9|D5ke@qvօ𻹆~}hWwts~cϯZm@O&{6tR;x"k ފޅV׼ fDar8b:Z~U7iiNy G_yOWa۰|ׂw"b|X.A<ӝ3@o{e f/^ "GeGqDud8hb7P>F'[.c^9\pF&RDB⾽cIA|լ^ /l77 h5XW /Wҙ@E`D 6x!Y٣%񯎆1M_r`g-̚\(Y>0k7 X]ha.zAP̎x>U<~@@` !vctrK/Ύj 3@3Q@e@ X:Y%]^= ]=NcI"x;]C@@ 0s:Y%վ_|^X5 oJB;@@`/:Y%%WsWF+<5gSFI}3<'/AWoH]V'7T4+/?qqS`K|ϵ|펙IwosɸxE݅:[ûqWQI,BiZ(ܷ>%xzqs ޟ`"E_~̜m_Sxd<Ί\{#TO<W6=o4ۺ͊&_nEϴ'j:;؊v'gZnz7dpWPk1x1weUp>'eZwg8fPdC&jNN|\c6JA]vuvJ=r%޼cohҽN[z}zߧzZzToi:l+皮nB ƳƸeܗ?z5yHz|f\s vNgR>PcjUHǪx븾jXj8wXpctlXyzp/p_ hq4n>{,mʏ״aidhOYDHb͑V}z;e]i_~zIo߽t%rIO7^ >jM/CxsOm/u}q-\z0WCat?]%׋斞3tgES6{ځԮZO\k~wti,F/k~W'$?1sWƮݬIʵ'&T?}tX]U< ϓQψ tm'?8߁Xww08W6x5HdM蔴}u5kKw'$+4&|U4&8r؟~j]+Y}~[뇗A,ͱ󘩹_{su;ʍt/g}'c͏h]LJ& oDž5֖8]T|ȇTyeu\ϣ+=.?Q] w::?L^CϑCwp9t,:cy?w*ܲrO=r3Uy-;6Mςs Q_~~.d. H\h,GDѼ}Л9?˯,ie& )eGilil(5@3ѸdcȈϬJ-Ymfʿ0ȞJI_(^WhOͦC}q1shal+әS\:17c!s}#u_?I585[unjRsiZzNkY9=C䗘/pTயg4VS*c\̺,GŻn^YyUI-h~X~rT:>|9z}6z;_>ڧGSyj>>ƈ;XqaY~}jh0~ m RYӤ xsغ:92n7-~~{ryKt,GE|_$9w`_)cQnۈ/-<x6̯s{[)῔GsOZp+>Ygsj}g_DJa[YYOE,dV싻c_Pq=ܶL1 ̘6IZ]̜M|J1XTµñwz]>NZKq._H<5ұG꫍#v@ Wcv|G%6B,z[(zTc"=xmhz8V_X:J4zZ_6l6Ŀ?^ɏ|~ӑՏ̑hi~ m+'ILS^. =v6*]w~N.v=ۂh@%bFU:|mEQ^b.mOjϦo|-^.#jy1c>mhTGukՕ[|2.0;Χ1K1],uv ā4vP{G7)(xSzZQb}p㶙3|]wWů6=;ھzV?&c@x>}5({ /V;5+aMkX^ 4||Nݖ&K)_%jܺguNփ/-sn99vgM׉W9콰ksG4R3"Y~'yșeayb\r 6_zQ|Xuv#b{e`*;;ǐOzIvA2$$c_TjO0K׃q^:i/iuՑ辶K9I*o[^kdsYbq,O,.W}*Ӿx%3๰ ˑXcpus;4x.7|_ݧ-/Obi[^ٸ qm4WEFpz.-,WAz0xɧZlqmkc$74'b=庤=C v&=Иw۬Ci|CX &ע{~K*1=Pޒĸ2ǐُ=$[cI=\"/X[4*5@n|=ΞOl'q?Q\Vg4Z=tzPvm۷M2]J[f1qsĵ.BnlJVyDZ9bBVXJQҳ:bTh=Y&]}~7|Y@Kcy^~`ޫii[G+)VJ)e>rFqWV]>*74{W׽cO}bA~R`&ww跗Ḱy]_ANg:4e\\֧iHǥOFjl9+鿮[*vOuOc?7=Ҝo㲆=[@V_ےOZ`591j_>*2+א_tnA:N>Irzm霁\z889xs=ٚ-q|"LRωMbl%?<7񜃿tQYGWYZ۫,?9VoRc$RYɮHl"`Xi,.ZdyɇJ`}Hc4ŦO:fzuO.}E6qn#y&}V|^/JF<i-w4a}?tpo_zL|Pj ch30j^<#/.lcf5ނu=7ov7V=xo?G>i~yA2jaS=5 tz ٵ:uE^{|ydNiyt>?arȺiz ]Gӱǘ9AoNeֲeMwī;~>I#cv|azҹʶ_NaAx0^Zϕ0zpyu\eNyq~xUGߴFfYΏXocE/ɻ*~We.:eeA킔7R_ͷ;q'T%*F[ \MFWGMhĴRWvtxomhMb;&} 3L`Ϻ7~y>nIF,#s )56Ldr7L;C]Rfxut!98M_},>tmx J-w!üY%}ز -DKYr`1վ9ʨy|x߁y#A~ZQp<`?Oޅo&o,MSK2}\ٱ}"RO:f?S9}uͶG7ņ7=_OWȲ ,P/ZfX'Al.i񞾅Z58~5_C{s;A gڑb]st<~[py~@@`q!0)mp4R'o Jw)>p!Gk5$E=r,)̹;Y"4'=: E`Qݲ6ׄgwJzZ'6,9C rBbn=\& eiD9\IPh' %3b<\Al6=J_>\3Xҙo-87B@@@uKbA vp2# X :Y%] }H#x#Dr,|ڞogPk@ |,ǒH}F va'P,-|,ǒ.-$FooC/_'1I" @@`vP_Am^ G UM@ 9uKzs(P=SEr,RZ oF@ r:Y%r5\77bGr,bR_Rzs@ PuKPit87](f_'˱3Vo  d9Tt xxxz:Y%{zE 6H8󇀯X*<[ހ@@ p:Y%B@BP/ XJ:Y%]J8,.N~7NcIOGGѱhlOqW' vn:@+T[m] W Q\]Jc?:ɵ6iXH QWU\ݎ_` O~6x@>S'P=HeXxf ]jRvH#Zj>4V#A|tTGm( 2EJvqOq/dk-^8mc 46 L+ӹ|ܶ?OvS;y0rWӭ}>W+2'Ҙk~9j;gGP }s@TϲӸ׏Ftt;Ymy"Myft r&2X|B빏poh`zDizWp<5p.0^h}x8F [~~fG³J No<,|說Kk$?莇%O8*J7MGIp}£O\,9y-2X-17DE* \V5\Qdw'U,\8{zak7C>< HG^y!~=eXU>Ii3-LWk G_'˱ŷ=ZG"병vq/!-4[ xZǣ z ,Nc=6P|*/ nh;Y/1XbO>Yzl')wp^Ût&n4rWhXKݸZ˅t>}_ĕB'e.|S>kp;RVyXi2XL?,ㅳ[VI.~ðXoX+FNQhk8M~hVܮ?Y=]ꙊnȥcupFN8oOKg1Ծ"A>-ה#NcI<+qi&A Q_+sb E )^;OǐJXtZP/عh?FODltp 7Jݲí(W)˕p\ՕҖd IgRS8#,ly-9#c A[۸)u7$Đ{[lǗ!dPTTeHv~`S$X>}{ݭKW~8syZvIErdŮs|yb>aC|o)=WReSO:&%}f}3n27^SugZYZ&+r,Z}}8-Y;I&PӋ;V. ;?aXu-jۥ4?ݹ֖%2_WZnRܖܙ;:fn1mR|^wZm?o%xmD,yIy:gvٷ=sMnyX+FzrUв~SUf z'12d<?Ցy֑xPmc3}o5rǟK=z4I}:},"8aRl{D76ϼs[8Jk#?}'u2ӷ;2m/3Űm'+\ n;Dr>\O/Cf 'MXG>'zm!g?ڼeY J3&K^R}V Oey|lϜ3TK@$n4h4<enxg5J.Aг?NM0/g<[ nIu6-\wGqǟK;NCÑ]xovw*vvEo,\0*KY7{΋fWQn%鸦x|ms>Ԓ~ծ tjx֮E2~zu\F׽Y XtϾou.g)ܥ~6igv:d,3׷ߝLy2+!5YxٚeƵ;Z%]He{派B:xpB;%$RR<8mNF#ztI<&`W ?[#%ne$>H1@`1o Q|γy|kvd?}Tl`H~yW:eO\46|Ru%hϵ_cR`?G'-bdUml5QպR0%dH=anWr*]whsҮ\nm\ ^95sɝmowۏn׶N|q}y㵭!7k%ʳ5};~ S{tS$K|L0 WV՘cB:"ٔ++oxuF]W;g.5oCVLCits6?xp"'2^_9,CT>'AW96գ8CTﱭeuGW詅m9۳ӹ{&Ҧ.7_d,SN2oYlHgwM{Ǽ3d};:X˟sO(Cvoșg}yOTG>~f26V/9-sO韴QZ<eO-~w}ݤn]:}LVhP]`o:#LMsjZi<}w$e!O;dxﻳL`c>4uY~ve Ƈr+a>[n򡅿GJOk:xJ޹?7^:m!7k%~~ ؎zݧ DK_ܻ;jԋɕlrE[s;"<4ܯv-箄m}xGΛ+<2ټm+rwW, 7iY uzw9ycwJRl;>\r9OsnE[X;?6ڝy}pY/I6jt؅zehyyGQxu<ٺud(k#]?#g:^yoǃNm<8%]?~d\r;V7l%3^$u5;ENXI%"+F[mn{$,yIeqz^C%LR3=()z&Zϣn}'_wMn҇|Hؗ;hA~~Weeznǜxo}\w8Ww컡ȷT|9?U',#Y1Ceщ]9$}'kg-Y8n]ތk>]YԜDIF#̉"ˋ⃿Y+R&é7}g1[@3YJOG\KցR+h%?6h\d-;t&:.+>4QRXP9O ):S +ꭵ2?^v*QuzD=\^c}qx㵭!7k%Y#hty S&K^ҩ#%$(DD;  k%䭣Fj< &K^eŸ@#wMq@_!3z !ɒB"N/}AZM]%/t;;QLM,yIĐn? =%ɒtb{BkSt;@@ k%Gy:ň@/wMwT<6\pdKidn'0 'ɒ@@@&k,5*@'wMsDz<xtp@K]%/i~%Ao 2 #ɒZ@DNڂ 3&K^ҙ>8>v6jc5YNU!'~|v  M]%/D O- wMR!]b$ ӟ&K^?: H w(wM =OvȢ]5Y~Pcn l"ɒt6q-cng1N@]%/Zv|-hwXW%|uL!5H 5)U>xjP%9}UpE2f 7S7HtoÇ WEI:#e:On~/L/.r_'/RUR[2gI}{igY&)IjH2rUiJJWDzwUܶooJ":+_eL㺾K]xtmU&#sM\.%=י (k ʝ$guoD˒ښ5#C%4`\`k3XZGn#CRovp+xݾE]%/)I%}ߪ~Ѭ>{cic+J> wEuVύzWm7S{ۏUjL_>ZMm?~3/mH?2zul N]> }R6xb|"wF }jDzVDϫsм*sF +|?g:^;`-MG6 }IdGFs'tj.KR;-]y.v껫_L mTzZ풜.U]:.)JkDe'% 򍞇ym%Eu㵭! &K^R3w?̫Z׬q|.^]Z}5k`n׭{':!?ص,;~S|I;/g5I+*#39b>R{u^rY+mNϞ͏Ux~p\cS9 2Gw,h<+ofnsndjKw\rO+^%lq'7RAwٜxXI54<23߼T]N CJ{ڍ!P`)TȘ9sÉI}fĎ>2m?Kj,О?u-'+\mkhʿ1V\+;n1r[_&YC׮my+njr]vmoUby{(sZ.{f\F׽ ST"'(“C=h!-\;ّɘ}R^q}KݙQ*b@{8yӢO. @ 7wM\yg*qD.@߿%ĝ$-&;ets'hD.&K$Z!sO]/R,UNCX'a}Twg[vu-?LgCꃅ:c?:~jڣm'o|:hs9t?6.m}Є~/|gDrM~8g*1}ml`/)p7-ϿGqu/HArpdKu$H_`*nf~PEkPltϼ;U[>}ot66 7dd=yŤU=+ʘ98+gS|sڌ =T%gƋN9\uq߯/|;G۸t6:Hly"wG.>|Ygv巻չҲ?.w{xݛgZƶ5jӑ+g_@{_A3|^/uv9g 'םw$鮱Xs Λ-\Q.uYT"ݶ_Qw**JZড়\r}Oc-c5tɹhܟtPG>R3kB@ wM\VX>Wwt1@.}RVtmY٩o@<8>&_ӴuQ2Fծm}m;:G۶?gǔ;V,CW󃩵F^6Jmd~hމl+"e4X;W<8%K˲x 2?#C;]FazwlNsSE.Ɋ\:dS_}pB?.i#2H J3t4"Қ>g A,yIl\OgJw+oF*(_7wUS9\_҉'׭=ʹKFv>tdu#oBߋzҪZи~UYIډ7c8u8Wȇ )8tmx0= TE[(HjywWyj |I!˼%D%Y9S۝Q:RgC=yR@L+*mߥ_+Z ?s%*ӿx3"2K#ͩ'sy8ڕ xxuC@ H]%/i,O!F 0sk%9Ht+$@ k%-t` @M'ɒ㷊St;U5@f#wML3t;5L',yI8 n/J@>k%G#Fo  0wMýIz 3&K^ҙ9=*vvZ5YN-I!Dn'"!ɒtbz@+St;Y@f;wML?t;1LW,yI wnmn6 &ɒ@@@&k,5*@'wMsDz<xtp@K]%/i~%Ao 2 #ɒZ@DNڂ 3&K^ҙ>8>v6jc5YNU!'~|v  M]%/D O- wMR!]b$ ӟ&K^?: H w(wM =OvȢ]5Y~Pcn l"ɒ4!6x$/DW\l>r``i|x~ݾe=u!%u%9y!~~PrRjݘh^s%%m1sQG@ M]%/O}XZzgKwN6=QW\B>'}K&VuSriu{Uqz`7c9'b=tmKVJ6?UnqxcݿW}wg]NMIO]pY@W'S$th׺Zm3XZڽpUzhkʼkz )L=,yIEڥ{ojmqTr0D~ݰUG"[~/?2@5?/٬G"^~~npG<|&(B8_/o9`':$ߕ=W=P[]oQ?Xåj{l-lF7&ȫw. r jkY$ nZx!Zq} >]kM8Kj[ | ei=O]%/)yҮig~.H&t݊5&WXCΙ󗞕o?w^y/⾊5P)ǯ'ו}wcm_kH6c:dimŦ_?o]>j}~$mp]jJng`r4OewP_*68oAJw]R;9M }rnʛk'csKo|NHA"wM,oM|"x6w0+~0yy7yי`YG.UѾ_eGn&u7%uB f5߷z0|lXnGuH)ko/NVo,FHI  0k%%I RuEcf|[3 wWRpyedJBG]kK[-oUlpW$s|~pHՃKލH?fk|8O_亴@wM$i\x|"ǕL*Zgrz/ʈxU[뫊4ᮒ_'+a[x0QMдݜ+VM\!ٺ*զsfHr驌wޫV;शۭr:}x Vg[F@wM$kfio6 P ɜ1މ9@e:wYNN%63QW~pƋ^e|Քks4>6Mkk{{TZSs.ډN(T`>k7㧽UBM_*}!Bވ3#  05 k%%9we/*߷MVt6IU0 趏pu~] ews_Ʈ}q[݊N\MCEu [ R_QA<;/n[۴.N pJ/HA[r6Se,ɶb ,M;i|ԛi{h77;B6ȇxC1Sͯc[tL7{ƆSow?̱֚x{#߻Oˮ-njB &K^RD\fU9wG${v-YM bY"n\''J?.5J u2og+3Ǔ`~Q=ߡs瘝SzՃқԃY&RQuowU&y_YlٷxEcvaa N]%/iQG񿻁 :ʿznI'_ܓIj/BP|rm1\6m->5p9[&s\r  Px,yI /$hDE{  k%T%NU@.H]%/l1 t c| Ӊ&K^4za R  ,yI?/6G]%/xpozn 5$ɒtfxv AwMSKRH3ۉ6@@`bk%T"N%m@N]%/lg3DbL ӕ&K^:&ȝt @ k%ͷ,o @=pdɻA@@&b@@@A68d d+   >@@@ lp&\| e  `3 lp>($W@@@ `A}@&L&   |uRmB`mpBl-Ӆ ||I  0myFV5 ckLFGu*WDf\;jVኦ-n5JLꄾVmoPhl}2&9M3ܫ=vSJ Y=IՊ=RhIb_ݝ.hLꕑ7x̥jߪ_SjjIC   M?sn +ټ)vq1oԪToI(o&swV&sڳ*Y4K-F({Vfz[TyOm&HŋƮg:LyKR7ƨ*O1SD ~誌 c%Z&#Tܚmp7LYp@@>9kҡud8n˾og~ߒb_ZLa_3~R~ەT*^uԧgJf3{/n;2y:06u/7$n 7l{L\ɢ*bg~  0 ҪXpi?A?xVuJuWސ+m~~_O)Kt 'k[nbk KV'cR_-g;o颽> RXbw,Q^˖3wQ)U=7ْ`9MkreJorKo\ܫIL˔Z`;S 5H\CZ>r   09SHj6mpd77iyZ1Q6._Sk$qm:cU~fRJe*cg;o36Ϲ~ٯ.bRbx0[qǃ^xi>MYbu1K>v97i`8S{` @@` L+G=PѽTt. qf_5|vK?VrzWXU9kis*碻owPEre2`>]U3Lِp!tny 9x'9ddO=Q~;]tǏSϮ=`lx5r:vӎ\>C;nM_5T-CUqd:t-^[x"uB~2L<k^]w;u>/뢷lL}GoJF^S2MMޔy!e5,'u^ 5˩]]jl-0T{?Uq<< l,!@thlh˕ے|Hy~ ^jGO杖]`)Mi|b=_&0m_f   P>A@@ a1 @@@0` l0lpaW  . w      P^A@@6s@@ C60+c@a;z`( pG   9  !\@@`1@@@0` l0lpaW  . w      P^A@@6s@@ C60+c@a;z`( pG   9  !0Y68wUR!z/-JNM d1}m4M^r |@@`l%קoHf3< ޫK>Rzl:eۥnKF+aUcqV;vlʶVmսP\Gw*JԊƣ6{I;$ه|/VctўyܸܷSc[e E7(UYtŦӛg*y}VtEU5k=ˋN٬#3Y~j۔=NđH>6a߃{\q]ݏ[TUHiኞ5O?qzkhRu?/j.V[O Ln;FSPzΘ1MR[ғ;Ty\㭃v~Uկ'T2_ ڌ_ ;{{#tf2GOc[UXW=Fբ?)}Q]|It0L+~clkoZD.k猥X1p#7d uQ,Ȑ*2d-o[D-m-dcg.NI;Cd^e~kΆWUNIMNi 5cgd {ښ5T>U+/):j9.$9GB%S.5fdNW»kig>[$qNWّo짟4Ci|leUEG͵T`||+[3|ƹN,/#& ?E?ћʹGܹhs|h-q+!k,_.Sʁ)n%&ꃭMR o|a'c֎E`,z[w_@F1w2X(Z^!tJKa18XCuO{=u8[; K6\^i͘wC$(_/Fc֋h9&(=yeS@={#{C:*xʋ+Y^\lh %0Z-l75@ʁ wf"/1]ixMi8|/]L_C{l֟bi΋8xmcX;[C_WA2=f^c>TlWG4nl>`Y &,n?@H&X(yM旇G}t3#͕\`~sEB(xcv퇟/5.p,/cF75vFi z Wq,]ʁ)nH,1 J#O 6\:e#2DZ!`$R1hxuLգCfbSq&hI\]kS bXE(WslV0Mg3W[ǞfG/!=ù=~cv~ ##\c\k)Fiԏ,mۆ1C|.C-\~s=}%i-ɀ3p̱*goA-\ִ퐭 s fLKGFڦw)R8 }4v w w!q1a$<C1y-#9J< {qNcv`N)WPv? t,:G!Hl7#$럌/E`h֜V;OǞTC.[\S[x5c7.->$~4ʋrȩ%qTyBǼ$Oi,ORsP,c `^8<Ҭ=/ƎC?1[]6XQׂ:& +mx 5NN\]V=LԴ~ǣwf_)oX#-,fq/xU=ΨRGhcCj>NbkieSߚĞۣBlKk|xZ]ˋp=/׉G53xx̜io$ BOzr @ʁۋsL#: ۑYa[Ѝu4Ҡ} R:mNEmpy]7bDKn|k s3hvҀ:2~P*>\;st[USTYzxGfVt Z0 ЁzOݛsGY؉2pRބy9j)xi]Pt\3mL}~e͇o;6E-)8S;"V7rD F`O_`5 HE^͇(vU.Y,=' uQJ烥ӻ)nGH1'zZH W7b'̊:G45 :FǺCr fSv~p1\a|{v^)7+KKq9g{ A`-i5AY}>ڟѣX_?'cFbMi !|pH9pq@`-Ooί<ޠWfa8W<3WWrLv{w~i7=nZ 7v q0'ߺ)hSʁFLyNYAR,;o\}BRݔ/հ}o񻛁 2ç}uZ:ާH9p;r@`EG}krhYUNB.yʁ)RZ}Zzʁ)R|v9ݶOkr @ʁi|kr @ʁ]}gӚH9r 㬟K n-i$3tF[JOʁ8~uJ73V\=KS9K49rx2#)͟-\6KjlwE~v/[tv8e7|{ГRr'>ڕR,.t<9jzƼՋ3oq:_wԶht 5{w&:rt/a9T.{ۆ F.yF~É8wU@ٷqNn{ݏsQyo?K}gI '/I糙ɀGҽ'ڭ˂Mm|7'|Z_C ݧ]Ma }mw3/|d|]|?:,o"7Js4p8#;/^scĥjyYUG2'o؟kXHIZ%~3淽DpeN׉̹YsWƉhy*\$98evt9w]ry-r+_RNL]gHg6tM;₇ϱg=AxvOD!/=1x>Ş5f+FMՎY Pa}-LG^ƾ?m~wyCg[;~Kgá5Fܙ5 7e-rLwZ|L0ҿfス(C,(uE W{K̏DWgo! ]* C:yN9>WkWo}b-.\AN(e%{'\;q6>9s3ÂyѬ=2zVHT3w;&:'v=R5_9g5+c`~q4sxl8}ef.Θ7z&v̚gs@o4kNVg9fEKǃT>9]Ӷ6M|BH%'CAdPm0T)9ZĹ8Oꎭ?!>[~iu~GR ׫`LW/~,͉^fY)df);4vB kwqAQ{ߵӓC5;w] o':jZ~xi٨-8b~R~ _㓦1<{*fG/`zPCp詋<5O>9/އZ܃׾>N7{K;iwGyn-D˱|MȎ79RqBޗOޅ<|0lAG9HyI'&ۛʹGܻhW{l BZMqͤL䐝%' گ/ {#ؐ(ՆARZ` ]}-Z5K~İ>.+`NdG+߶ζ`ѧfw-0_1sd5~ż#9B}L`kܶ;TY-e$NZ%H.H͆I=gZ]w9a\~YZw*Zi+,6ڢ5\2]}|Q뗱dBNy oaGK2<En$u,ﰵV=g:p93V+Ό'^U\76V:ޣiyA ?S=K|zW]. cn/qooݎٰhFq0 CgzeIv.p2_c$,Ui ]7j[d;I&|%PwG.IuǬe?0eCY4mYMŬ_y t:Hӱ`mE,E>CSf5Pc'&SR"cӬtD" /AP'+,M?GrZbdh0k1A fmٛ Ì45\Vۂ1!4}"𴎶XkKyyVv^M1^Evts9>.yOZlNr 8X:4=  BE{se˻oq@whN^MY/t O,Èj܀.Ƙj|L7W? *PG Oh7)tkvhuzk'7q{Xs_'}x&h?TjG[-ð(|U$ݔJeQ'Ka&iCKqT.ϣ}jj=UCi>X|86ᵆY ҽcf1n_,GDy_Gubs '·/碏[ϛD'`%_XH\.?Nc;.l؎yr \}TWOhfΚISpMq]zl7ۑ5A}gty= Fub -1ɥ1 xYޣ8XnP/˱|]?/r|z8 W)-\ִAh|{^W,V[!#XRH_95}-ES9x ا=pɎԛR|U`.IOzƠHZU}\vZQ.޽Ċc*qpVr}5kf7v.PS]I87jI'.1Q,Ʋ'(|0PL5ue }M /1ohbK}.J }.l烳aCN7 O(Omϴ2_H?xmR[H~EsUӧc<3d<jy>:G p^tM|vyLc-1c)K ƣrNo:ԾƉ ,ruN='x9_ZO}_Zы8XOK\tyncIByt}xZ4DvbÕ`滖J]ܫjF-.k5z>8vV?PKr4%\(Z3A9reȞoψtkAܵ(&=<烙~UN؉'(rT$ F9>M|akk۹|)Wv^F2$̯e KkZ LH;9_W߼>>o` e`.{-oXkI@ϰ*1Lr+_O]bzybQt9^;n+~[1X7g7vJ^cB.`^?>grh}#wˉ?ڲ|L.ʸ[4;;jNҽ폦vb>vtBSr/f>K}wjY]cg$aiiebQoW[::rOonY~ =kO3jgWǷQk__$&i,+F k/#I Ё4_L'jh0߳ oz k){r=|`h6XV3je>qUv r!mg 8̲胆dkAh4e#s{Hnzj'Wdgh|Dkk=^a7kI7X<ڟmoղ Vώ6=izv"YĞu'ͮ:򤞈 Og< 63TL3xWw7v2Z9`V7E:=:\{Ф=ቑ-5mu@y|RfE/^io!YKt's̚k,?toe1auVx E?(pt'}98PZv+ɭe_C[ѥ/ֽwJ˶ni]M=TLW 1r};Asgvcy)留絆v_,2odh_s<'Y !I9/H.읅L4kjLDR Zj>2[mωtD^Zq҅{,I=a9Zl,&sxE{4ٔP2ơi6+fKŻ=ؿL;nk$`yI!z) tyRIhϗ,G@|0$Z綷~8*TS# Qip5JL1ޖkad{GZEtۻk.ICӰ&b:rv!~c\Ǿn}Ʊ+O?^U.ayj /\ <$ֳ?'7fFV|yo4=>28Ołch %O^c:g:}:&[n,D_[KsM>U#\`$I_l!؅bS}Z, `gQJ<| `ђZ[޵#m"4Leͪ#ZNa%ּRT<'cau|WwV[<>]tsC.b6OFxB䪈D/yWڞqڍ\uL(x>8?݂۽Y̥RܒOG+ruΚsE;nЀ<Ϗ24OONߪg-+ezI~4y^|0KwByXx rs ]\WsI.3\uWk7Wv<7/;Ojr<[!ص(֦Oo:1_3{'9V.GBe.EPݘ͛;Mw`ľtZ⥕[O1H9r @ʁ~}/ijʁ)RXl}bs8şr @ʁ)H`?_Ԕ)RH9Hp?@ʁ)R9~)RH9r`9ʁ)Rs |IS9P w׸07'՞~)bI9r`_E(T;ˑW ^P&nk%_s38RrV[y [ϛ|nmoUcpcHsH9pc /M`9 _} oU2ƙ|Adf>:UTNdk+浽xDioneAzSTarRf+=(WN.t\~]}4=E'ݏ;Ey+1&]S:5,>WCgtɘe;pګjo=a;- 6sϪ]/jԞ18ܭߥ q>ɞv{fi^y廒/+d,8m~y0m j77!kΚ_=rB߄1{Y+orTFGz'sĐS 3{`jK3aqz!#Eա~HwO6p^"ΔXk7dB%1oi S]:Nyŏ;Fiٚx.б/wIGmǷ5Oy3;q2pߴ3)y7_4n_Mtm>z4V\-jay9٘ZH%}9ҹq.-'A{N=E=fw |:i[RIQ&YSލ\ɐ\"x k <^v=sE!'G3hi&G=Z0wU# (|vX|_]haN%cDiht?im=( }hDpk\syW|O? r '^+md Ξ)ۮ7C.lt޶馭AO>!{x}{ֻ/o'ybܚ/>bNDL3ӞYop?ԟR\0ϛ t^v[?+x#9 B/q*!۪'h?dgijyw ,"O[t+B͇H[ bJa m?wٰ;_B,ǛvF4$ Ͳ:7>Jk|wQ[0in/$ Pizu==ўv@ | Oso{.`=9\}D,S%u$w=3BhWnOW&Wr>Ujo?y%{/"V't,/})_Q6'z1kJQ,VU`qt𝴖cTZGǷM>ozZSܿ>dsj\Ckgv^suM_'im,O~>N|{*V&ӂ[Vo4}lu.Fb_W+>mJ}mtF=CǭeM?tЍgkRhL@bff>!q}-Dl0e۞8Rc__Vt9ڮ{SP7g}/4c ިLcfr1s =V\#8p);yG|g-4!ڔZ,13H~9P'1!E~tg=[GeU h+OgH ^_@S{{eҙ/cΫc/P@zo5%-G_}t2S_%7LI˻&-ǐ8 ;41AaX6#٦UDOFf<\pKJvjǦ;#lg;_YdfڎQ9_뻦zQZ xx uvRReGy\#)2oJVA<Ƅ<cS cK\O, ĤL/Bìܒm b~_n^.nͱh<<}=0^BϳseV77vEx ss;Rq)}f]b 3 2&c܋|;rm%=fuo,e-s9}p;t|1tiOp뇗ޡkXu$u'LCXNWRw (u~ kf]k׳XZkNW5^l<&/voxmh@ErmuX W~P{ѐ;Myr7w-A;c {Ǵj8]spiNlWCĚ>P>paz>`DkKkQEH>mGm W5b Ǒ#)Bysx.䬋޽"x1Z,yplfxrٷ9`FKKnRGUZGxh-ș-sjKb ":k6&-5l> ,:kuÿ#<|uְ2Of3碴Fgxff0zp#:^OZs ]_8{Z8Zo~AKm VEnGXFJ+Fx 1uz{.:vijoF r8&y9In(^Xc J]TM/C:̏$' RSe>$qsZC\g)mC_^@N=JYO7yh/FQIڱvè^Xk(Wi'1̝ 1s}}b~9ZZp~.Xe`~i#}j;Jc>HIw%Nʳgi>EO[;uu SgS[.g/ %'v*wIwIH2#x3ړRIzuvF0Wn5<@{*tٽKYa=z7҉zwz{m{7)Ӝ6oFbq}eUӖRF =u~ po5_|vDd%Zזx[oEpqK6KRIW HR[)Xav>v}D^GkQt #ӚqY'8bd1B!Ӿqm2+iB1~x,$R<Ąs2z Je0']k8z7N7gIy'a`ẠC' ESY^ >ePvDu۝J5/zz ٓF 4I c~d6`O/C޷'odk{`ŷ\8.O毫C^}ځJ >{{*ߵ/N>3Wq)/-t~~,Hu u֙\KbKc]!ƃ'@}|i*y7_Ͽ12acQ/zyFs; &gЋZw@W (!撣8zc.ҝkwbb/jm18s1\D{bͭz?QtkƳ}q~/٭).zLan5+Mnԉܔy:OnGMp\g/dN揁g |)cNv7|76+[co|wbnZd>zc$<拵]Y}1}<Ќ9ky_bW/Nx0Vuol=n Ƥ2;mǴ- bibC g凈g\TTYѩo-ݹܙ$^2LՔp4*>s^쳻iA9}{<^g𶎴/4/xGfvgm[n>V%Of]|O_;HJԹ*oIj V?f`Z]nɞq.m[ +АߘjˎU߱k)[uDOO`G\ ۮkg.1-fYe b^CٌcKyijb)kvyN slf<0Mw>>Kr$^?_Yr!bHl\/xlGdsnǝ+-ld=JƸ~N%UGBՠya*-?ûJ跥 ml? |8_l+xW[y*ҵDM1p ehgA]>u.b/(kt,w=#yT>̃shqt]zॎ[hHҺdWl%e6{ji\cV$(f2ɲkd G5,&*M=ϓ7c|X~sUn취Nl[4+ Z, 4xS{fK@-Kم3ζsjsK, &ڬJE$@$P뿎YB  $@\BHHup1KH$@$Pk^( @:f IHjupm " _,! @mzT$@$@O:%$ MY/HH P$@$@I:6R ?cHH6 PfP*  '@\u &ڬJE$@$P뿎YB  $@\BHHup1KH$@$Pk^( @:f IHjupm " _,! @mzT$@$@O:%$ MY/HH P$@$@I:6R ?cHH6 PfP*  '@\u &ڬJE$@$P뿎YB  $@\BHHup1KH$@$Pk^( @:f IHjupm " _,! @mz\S[/ҳܗ|o蝗̔PZ\y˛K7o( \*RZ$@\r9QrKC6Ғ>?N__rGy߱5;7>o_:4[y*'-}F?)Nj >?GB9v,NW|#>[;PVΚmin}=)iNL]]֓eVk5jMs-dyAAi;]=l=-}=N{g {(]KWVMFiiwijqgK{{5gi?)mj8 1im ACS!Pǒ7E?#Hs%hgg~,ϐ!: o[=// iyJOKþ i'Р ?ڱ>Of-YM :-\00_ 'w\>ʈ>Շs(ۘ܆Uv9hVgvi{]>Τ.NK5h66!7?~Oj?k<CtdDkgU'VA>UE;Yq_Je©]d?Q]-EIwO?h[3l>NÍ%W=/܉={t:`k*܏YkSm5:*: 5ؐH~[ QJN_&=yA?s2Ik65>nOO.) ~8q KC^i A@m71«۵" ' @Ɠ]j5Yaq.ƥ&ZL5[0J(ƏPG=Y登DD1z]q:ÅvfNj߻搌 ap E#ߙ{sf햦Ғk~V1T@zœڸ[~bl02+ `3kھЀf[8wO&)%jH >l|툸gRP.V;niݙ%&Gۀ\hg'offʅ=&$_L/|qBy\K^5d•Y:8;88]X/+ǰvgut1 S+G]kthDqIS+%Jv1WC/NI`*:8Q9hrڥwQݪٜ;O_9fzK¶ ZM>z|itGuaT 8?WrzpGq&W.Jׯ7vA/LƩ`.}42xTtQcѺ[yĸ[~::24vґѤUSI3Fk f?bn߻]X)ڽ{ࡣ;*:&lGz4E~yT&[Wd KGu3ʧr=k!՛^s4vmx>gacfgKk!OC8F\]X::E6;8Yڡ=rfKq?EXKˎ>?\7lkw;紛e`HS%{,F5K¿b68hhx_c4ۏky̮z=c?yC3pT?`h5 i#67yùFXxmZv7J7?_tgxwΣC,}/ƙ28W TN/c6`٧ʺjeGDG%~oպ >6`%1Qkova5qY6{v}b yѩ-rcԛ$9[ !DC&`ešj7ҏkr`kz?NY25`ӆ|$jb%;4-;g:NsvmZ=$6,3NkJWFc}Cchvڅgبr j!p-n,իw"$>lNNd1_7AJ|z9܇exG1'䡟X׉|j.C!8hhݖP>!ꁳݏ5=++.icA: ދ5\ ҉yGƇ]q mPODmXàU^o[|5<%H0FXaЈVܳ+}15tk\=c9bĚGG}kT_ ѾĖƺ{n?%׆|oGk{iWKiad1z^}Z&죕cϱtҧE6kq3,7Ӛ=mlۇ,:P~{==ؓqR Ȋ]3E{l,"Oq`W{nhLYL$05:XZ~0<~F=I?^8ԮQ=72~={"0BN`}F!6'O!F/Olʆ>q^<_ _h{~ F5)fhkImɳhx)<$W1wK>i%`>jSLwrIˠjRuG?뱴cc%]3P9il^,nՔ;xlRQ:j纊j̖9Wz~؋e?,u<ރ5?86;y̩ߝSOo\µ?^qj᝛:kiyBq^qU4= QzבwO7BwT<[8In}qY]?`[,]e}M" _YU#t<LskL"IHH yhЖūL7J:XKLw]Wgi $g\aC[t0|nTgZ6H^7{kK?N4hqp$i_|cC?I:x+P;lK4ѭ?quơ O}r~hjMf/HI/&?sJK_$@$@3EOlA}u'U&/4~%Uz2G;N zEӓ㶵^϶cω>n&4GgV ئVQṞĴ9 ܒwMj7㚮hz79T{r~TEiQcv^/ nOb7gՀjoWzWtX;V*#~د2"qe&#XCIiu9kZ[w{k=\Z"  ՖZj䉢`;=h"T+_tݪ=էz6?XK',,~Wkto7aצ>q:Xj"win}=,VAܳ=wחMV>q~Ye5  ˛Ag8rjsB߉e|i0ePwMZncKbOw_-jr/73~߂OW|oenOOZ, V-XM+kԸ?Xue2rpyIyHHr't0UbJsN%+Vlp!Jr% 3>7-j,C6;dU:c~FYnb+|Mézk6= OR}Mus_t9S^! ˗`-vp>;Rhk/Z`vp{u4j>kce}iCsN 444ySɾC9osr`]g?h/AdZ[k:tjۑ&l<@NyN$@;jYJ|#ۖ.>xr,eX1uj<}vE+Ǻ}oUTS"h:"O!L7|gH߱57ߵd|bp x9`ro/óܷAK[>]O;Xi_  :Xu:׮/d^xr؍U`|T/?X={/\b>،A$@$p9:Huu򶌂?ظvU}D^ڵӍ,+<֢_[g-'eJc\_?H\IH.^c<=亇w5}%{޿oȚ<ԟ!.+')X3'  K4_X_J@$@$Pkv( @=eHHjup-e# g\, @-ڡl$@$@L:ke# e]/6˷ x|gwe77ݥýk;Cw=icD_.CxH=1ǹrߗc\'r?y*^_7(n܃rMR^R$6M'erRvGf /›uW|ҳ9M񬃨I7yΏNxdɪVAέN| x[Lt+ }_<{t-}$ H9ʵ+D_ɽUn=&u7ϗIQ|WvQ"_yDI8?$_1g\*%if#e͡K^-_ǗDd,pF  C "A SNWVb_3 ?Up1gz;2bn33 ?Up1gzPNG  IHDRTIDATxѮ0_~x_0c۬ 8@`6]:@[Э;[O9fkR[-+adޔw,! ݚOUkN.b,n}Ee ￟??Ǒ[VȤK̛jٻi&*yP?8?_tiEgȖf, #ͻ`'~NՔ1k 1)kk%fL瑆cA{%R`dRE/:ﮥ8ˁ45,%H)4/WZ<U 1:g\5\:F'׼gw s@0=~q0y+˯'KwHRl/.::@z 0tn}jxe1//@+i(utK%tn :@[-A薠tK%tn :@[-A薠tK%tn :@['qj|pw +ǑY*r&H0N}U:ΩϟYg_֟'U^xSxkʫ4ŃDy{&>?=_#drr7v{ :@ 2&eutKЁe@O[-A薠 4L`tK%tn :@h :@hxkP5A薠tK%@\x$}wGWΛE.7#1ҟL &:@OǴ,:-:[ޮtbJ3Ш`ޮu] a*/)e/|UxCSx NA+F~}~>{uC`B-:oy>}ݴ|r/A(aV\4LGXDO{,:@[-A薠tK%@cD tK%@W`N%tn :ז"tn :@~]|6 >K A8yg1@UǥcɔYu캯gZt t u5?Oʫ_C{Z))' a u }~>{(cW{C:ͯ-r/ラ&85^P:̟I{;_LI<.:" tjZt0F薠q?\[-A薠tKЁ>92K:&@]\[tK%tn :@[p.V*14r\Z7>=v4t"r ЫmXɣ+FY :fx.VP]_k֟'U^xSxkʫ4Ńe'! 샑nnȋΩ`V>?Ηl֗\d<McNpQ8g\^d*?Z< DwLb[j ŬC`dY'K!a&}ѓWu;MpjɽuXY4֦̲+hŁ[@E4@^-AeGOB%@ ^bh[P5-a-AhRW +:@[-A~:FUs5 ]au8Af:Fhj &cmzY_o-Nןԓn]W18l#kr(5_pp @3)x[V{3?Oʫ𚫷kPk9֫4Ńò4^|"FWubǯW6:?#ǟOu/:_n%uO~DThvIgKh,Z-gK^H&VL:0t?8+A Cցĩ} Ag's't?C%|b;ڦ/:<t|u(@Ёv6 )g3 :@ogtz&}9gx] z:$J%ϸcOxBЁxT{WR Ba}bǸ 9G֡A.fn$aP[ k7G䫔 mO^O6D/eEe+8>.EZjnsDǼJxqr^7wd~qruU8Sį6+gF.>*|o DW x\h'~dɽ`8n̞ք MT2 :W?5k|Iowy/ _w˯8f!2:Ējݻ2.=Q7u~H\kx#{ {[E FݜBw}nio$m3^,_P[Q:j""8Fʿw~+VR43b>=E_lu*a-#/!Yƞ~<%АKJ E'u^ :h3̉cڣN :/Yz6 pEg┱$RtuN| 40<չºFDN)Prw\?O:YG<x{NU^ǭF^Ͽ/xx'wѢv)/zdT/SqwyB?+ENҴS-:|ӽ>uQ}9]N5q5uuc'Ћ@T͔z:gz,?{|EN ^Ы`qhW̵O8KЩH$묛U/ %"}=[m sF{|-js`Wغur`ˢS"`{gIz MhuWhѹF]wӢS3Ө}Agx[TyJXg+3VoH j z oz ozI{X<ׯ'2yxdTdqܔC#7@Q#?tf7mJRZtr@%):sg`V:U[TOM N!6@[N9?i"tҜ% :@[-A薠tK%tn :@[ЭwWxw|ɭt SR?:aWu5Sy^PP3T ;CNZvtJEz|"o5Ōct"OҢAy zkzgwꝡz5h02d~maY,:SOe@t]tn :@hmzf73>82FށMa_yJyufIqfYpRytJc`s+Y}ԋU)P. : Wb{YpkozJẴ3,R2,PL|ze"X|T)N lѮN)᩹Z^x˱m8{nYVyG/Wyц>Rnܫ8P`WEZۑl,ҁ5pfjsna`偱5/ _O^]cY>q*{-5LrmUJkOāi_$rxI\ʿQCU=]&TMj@kvn]J/w?*?|sMS]_/v9.t_XI7mZB>{  +a\@HxFOme /ef޽^iG|uw:_lWNpC8' P\g=g mm9o{ID/}~PGmjmx o=NxM ] ~IQ;wRs49 >I7mZB>{  +a\@HxFOme /ef޽^iG|uw:_lWNpC8' P\g=g mm9o{ID/}~PGmjmx o=NxM ] ~IQ;wRs49 >I7mZB>{  +a\@HxFOme /ef޽^iG|uw:_lWNpC8' P\g=g mm9o{ID/}~PGmjmx o=NxM ] ~IQ;wRs49 >*B*phZ/qZ +7 midsizeblue1)56CJOJQJ\]^JaJo(ph3f*W * +7Strong5\ :Qxl39k$dd$d%d&d'd-DM NOPQ[$\$a$5B* OJQJ\^JphRR :Qfont5dd[$\$B*CJ OJQJ^JaJ phRR :Qfont6dd[$\$B*CJOJQJ^JaJphT/T 5anormal1-7>*@CJOJQJS*Y(^JaJo(ph333FV F lJFollowedHyperlink >*B* phZYZ 6X Document Map-D M CJOJQJ^JaJ2B2  r Body TextxHH !* Balloon Text CJOJQJ^JaJN/N *Balloon Text CharCJOJQJ^JaJ@"@ BY List Paragraph "^B1B Wkapple-converted-space>B> %; Footnote Text$CJaJ<Q< $;Footnote Text Char@& a@ ;Footnote ReferenceH*Rv!qR F%0Unresolved MentionB*phq bob .zDefault (7$8$H$-B*CJOJQJ^J_HaJmH phsH tH P/P .zHeading 1 Char5B*CJ OJQJaJ(phPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭Vj\{cp/IDg6wZ0s=Dĵw %;r,qlEآyDQ"Q,=c8B,!gxMD&铁M./SAe^QשF½|SˌDإbj|E7C<bʼNpr8fnߧFrI.{1fVԅ$21(t}kJV1/ ÚQL×07#]fVIhcMZ6/Hߏ bW`Gv Ts'BCt!LQ#JxݴyJ] C:= ċ(tRQ;^e1/-/A_Y)^6(p[_&N}njzb\->;nVb*.7p]M|MMM# ud9c47=iV7̪~㦓ødfÕ 5j z'^9J{rJЃ3Ax| FU9…i3Q/B)LʾRPx)04N O'> agYeHj*kblC=hPW!alfpX OAXl:XVZbr Zy4Sw3?WӊhPxzSq]y L jXZx%$'L jX[ 9Zx 9< )qTTZx&L&HL&L&L&M&]M  $$$$$$$$$$$$$'4 jt"%(\+-146w7:;>pAC2FG JLXNOYQRTVYZT\\]5`Jb;efwxxlzzo{{|}v~ZADGPYZ[\]^_abcdefgijklmnopqstuvwxyz{}~,b &iKe -@sRYt\ffwxzzzz+{A{l{{{6|||}}ZBCEFHIJKLMNOQRSTUVWX`hr| X4X9XZxXJQSPWYU\^<!!!X@  ,@d  L(  hB  c $DdP8c#" ? b  3 #" ? b  3 #" ?  hB  c $D8c#" ? hB  c $DdP8c#" ?b  3 #" ? b  3 #" ? hB  c $DdP8c#" ?hB  c $DdP8c#" ?b  3 #" ? b  3 #" ? hB  c $D8c#" ? +(  h  S 8c3"`? hB  c $D8c#" ? hB  c $D8c#" ? b  C 3"`? hB  c $D8c#" ?b  C 3"`? \  3 3"`?VB  3 8c#" ?t  S 3"`? hB  c $D8c#" ?h  # C"`? n  # S"`? n $ C $3"`? n % S %#" `? B & B D1?"6@?NNN?N ' <'?"T@`??NNN?N? hB * c $D8c#" ?b + C 3"`?B S  ?)0  qTrTTT^^^^Zx%L!*Gt$k*t'lt&Ii)It`dEpZ07tt[t*t@t@t*t@t*t+@t**t@t*t  !'xq*,t*ty*{tK+txq*,t*ty*{tK+tx*,t*ty*{tK+t _Hlk511036501 _Hlk27408386 _Hlk499558866 _Hlk499623790 _Hlk18075056 _Hlt17991984 _Hlt17991985 _Hlt17992157 _Hlt17992158 _Hlt17992076 _Hlt17992077GQQT X X6X6X7X7X[x @ @@@@@|FaJ\T]T7X7X8X8X9X9X^[x]* o[xo[x>*urn:schemas-microsoft-com:office:smarttags PersonName clT]k t o x W]T\ !%!i#r#E%H%&&('-'}++t-w-Z0c044;;= ===? ?1A:ABBC!CCCEEEFAFJFIITUV VYYu[~[]]oooooooooooqqqquuXx[x o -%<%& 'I+]+66@@W[a[]]jjmmooooooooooouuXx[x33333333333333 !"%'CDGIdehj ./24FGJLL//00S^ij      //11qFqFGGLLLLTT^^^^^ooooooooooooooopppp.q0qYrZrZrrrrss7s8s8s:s:An)A@2>9H:Fz(]JM8Qj@`T%Af4C2j8A.tD)wczyly{a}$Բt}*Kh^`OJ QJ o(hHhp^p`OJ QJ ^J o(hHoh@ ^@ `OJ QJ o(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJ QJ o(hHh^`OJQJo(hHhP^P`OJ QJ ^J o(hHoh ^ `OJ QJ o(hH8^8`OJPJQJ^Jo(-^`OJ QJ ^J o(hHo ^ `OJ QJ o(hH ^ `OJQJo(hHx^x`OJ QJ ^J o(hHoH^H`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hH8^8`OJPJQJ^Jo(-^`OJ QJ ^J o(hHo ^ `OJ QJ o(hH ^ `OJQJo(hHx^x`OJ QJ ^J o(hHoH^H`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hH8^8`OJPJQJ^Jo(-^`OJ QJ ^J o(hHo ^ `OJ QJ o(hH ^ `OJQJo(hHx^x`OJ QJ ^J o(hHoH^H`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hH8^8`OJPJQJ^Jo(-^`OJ QJ ^J o(hHo ^ `OJ QJ o(hH ^ `OJQJo(hHx^x`OJ QJ ^J o(hHoH^H`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hH8^8`OJPJQJ^Jo(-^`OJ QJ ^J o(hHo ^ `OJ QJ o(hH ^ `OJQJo(hHx^x`OJ QJ ^J o(hHoH^H`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hH8^8`OJPJQJ^Jo(-^`OJ QJ ^J o(hHo ^ `OJ QJ o(hH ^ `OJQJo(hHx^x`OJ QJ ^J o(hHoH^H`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hHt\^t`\o( ^`hH.  L^ `LhH.  ^ `hH. x^x`hH. HL^H`LhH. ^`hH. ^`hH. L^`LhH.h^`OJ QJ o(hHhp^p`OJ QJ ^J o(hHoh@ ^@ `OJ QJ o(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJ QJ o(hHh^`OJQJo(hHhP^P`OJ QJ ^J o(hHoh ^ `OJ QJ o(hH8^8`5>*OJPJQJ^Jo(-^`OJ QJ ^J o(hHo ^ `OJ QJ o(hH ^ `OJQJo(hHx^x`OJ QJ ^J o(hHoH^H`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hH8^8`OJPJQJ^Jo(-^`OJ QJ ^J o(hHo ^ `OJ QJ o(hH ^ `OJQJo(hHx^x`OJ QJ ^J o(hHoH^H`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hH8^8`OJ PJQJ ^Jo(^`OJ QJ ^J o(hHo ^ `OJ QJ o(hH ^ `OJQJo(hHx^x`OJ QJ ^J o(hHoH^H`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hH8^8`OJPJQJ^Jo(-^`OJ QJ ^J o(hHo ^ `OJ QJ o(hH ^ `OJQJo(hHx^x`OJ QJ ^J o(hHoH^H`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hH\^`\o( | ^| `hH. LL^L`LhH. ^`hH. ^`hH. L^`LhH. ^`hH. \^\`hH. ,L^,`LhH.8^8`OJPJQJ^Jo(-^`OJ QJ ^J o(hHo ^ `OJ QJ o(hH ^ `OJQJo(hHx^x`OJ QJ ^J o(hHoH^H`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hH8^8`OJPJQJ^Jo(-^`OJ QJ ^J o(hHo ^ `OJ QJ o(hH ^ `OJQJo(hHx^x`OJ QJ ^J o(hHoH^H`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hH8^8`OJPJQJ^Jo(-^`OJ QJ ^J o(hHo ^ `OJ QJ o(hH ^ `OJQJo(hHx^x`OJ QJ ^J o(hHoH^H`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hH48^8`OJPJQJ^Jo(-^`OJ QJ ^J o(hHo ^ `OJ QJ o(hH ^ `OJQJo(hHx^x`OJ QJ ^J o(hHoH^H`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hH8^8`OJPJQJ^Jo(-^`OJ QJ ^J o(hHo ^ `OJ QJ o(hH ^ `OJQJo(hHx^x`OJ QJ ^J o(hHoH^H`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hH8^8`OJPJQJ^Jo(-^`OJ QJ ^J o(hHo ^ `OJ QJ o(hH ^ `OJQJo(hHx^x`OJ QJ ^J o(hHoH^H`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hH8^8`OJPJQJ^Jo(-^`OJ QJ ^J o(hHo ^ `OJ QJ o(hH ^ `OJQJo(hHx^x`OJ QJ ^J o(hHoH^H`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hH8^8`OJPJQJ^Jo(-^`OJ QJ ^J o(hHo ^ `OJ QJ o(hH ^ `OJQJo(hHx^x`OJ QJ ^J o(hHoH^H`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hHX8^8`OJPJQJ^Jo(-^`OJ QJ ^J o(hHo ^ `OJ QJ o(hH ^ `OJQJo(hHx^x`OJ QJ ^J o(hHoH^H`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hH8^8`OJPJQJ^Jo(-^`OJ QJ ^J o(hHo ^ `OJ QJ o(hH ^ `OJQJo(hHx^x`OJ QJ ^J o(hHoH^H`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hHh^`OJQJo(hHhpp^p`OJ QJ ^J o(hHoh@ @ ^@ `OJ QJ o(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJ QJ o(hHh^`OJQJo(hHhPP^P`OJ QJ ^J o(hHoh  ^ `OJ QJ o(hH8^8`OJPJQJ^Jo(-^`OJ QJ ^J o(hHo ^ `OJ QJ o(hH ^ `OJQJo(hHx^x`OJ QJ ^J o(hHoH^H`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hH 8^8`OJPJQJ^Jo(-^`OJ QJ ^J o(hHo ^ `OJ QJ o(hH ^ `OJQJo(hHx^x`OJ QJ ^J o(hHoH^H`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hH8^8`OJPJQJ^Jo(-^`OJ QJ ^J o(hHo ^ `OJ QJ o(hH ^ `OJQJo(hHx^x`OJ QJ ^J o(hHoH^H`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hHYtB<(a}y{k" F%Aft}Yv0 a0<"Dzy2{*\ZN!h.*>9H)wZ3b>C2jn)A8QA.tP=22#% 54(]J         BҶ$        z]        xDB                v2        T:E        (                 0        60        g|        V#        ns        64                 Ύ        $        V        nDR        HQ        r        T        |^V                 P         ,        2OP        Be~Vs[8^+UD"L&zL(jfe?z- Zc@D&o$n2CiUXWDQ8}T 9OzL9PkoH\dyc,f_~cxbLF6 O'(?`gr CE]=j=^=V04^?G{*E^dmES&'lR:> =B&C!0)PMn?w7cyPTndo~Mz,fZOe\{*_2 IbirbzS(|g"7e6 :h050 e6K{-3RmuOeeRSm,$9Gkz:C5`')TU0z5y~(<{M<]ap#zLh"H n2T Y? $Bi@ uo)rT CMd % hK3h "0 g{ .- R:9B [z18N"^=<]Y}a@_=O)xkOxkOvO>zX.Z^ L9 > @^Kf:U/BTB#IYzvTCh}jO !WOp#Q>l2U=R)sNXd7nLrR>l`6Yq}^RB _)}-uG!Yc;R5-el:a0`x;j)R>B _0R% hzS1LFH]sA`~Sm,$I8r %*F2(}*L?J,(<{9dOaT3*nI|o~q,;]]/ `~@eN MG%ho~LQs~lXNp|'Qo k)C*W=4pQ|--D3i2zT Ib914,?X,J[3iHpl{X%2b,oQO?M?_bHhhee9Pk$Rtg fxbH#IIABcGQj2`79Pk'I8! JHS'R}DTJ;IFG3iOMCCJs;Ty?"}IQ&j0@ZjMT&s2an11*)"9MT:M7AD Ib9Yh"Y%K@g>$6%fL/.IfNt"zt$SA: QK rF7aP 2yX *c 9w JnCT6 <]+ 88$G- XDN-DQj-*-wk`-[-q-XWg".# . 6.)k]/.weq .S-. U.Oe,?."H %D/(/J5C//n/Htr0 Ibb 0!)p~0)09~I0/0=|j1_o[z1o~/1:h_Y19)14a kf2oHs2JnC)W2ndy_X%2#tTSLx2*2JnCA2Oiw3i2}n2G3Jtd 3$3ndK{-3]]b3cGc3b23#3<]q.3B3Voa3-^Mf3Qh3|3 3qz~4&q_4m"7 4 gr404muq4zL85vqiH/5A2S@75x5R:5{5J5+j g>$6an)6-~T.>69%}cJ6'as6o@x#6+6* 7m|~rF7[z17o1z7y!8E/%8z~4+8"Uu'8Z9!8vOG8 d490 T905g /991Z9 9Mu9O)ZiT:f{2O/~: Ibl:tx&R:F)3e;n6d;&A;zklv,;H<9M3X<;3Zo<xa-> >D>G-,L>VDG"?B _@ ?4,?4,? I?O?M?E<=W?X%2Ty?B?V?*? @ye7J'@?jc@{Op@K %As@`&Ujb@C E@+6E}@4pQ|n@q#\A;3Z2AYAB*?MAS@75&Ae5q`BUIABOekNBx;$B#3ZB/B9Pk=B&C#'N&C, j][7CJnCNFMhawC#3Cm"CxTf C^=5DJ7AD}-u'qDhEsNPREEo~A|[E0z     R{E`~JE<=W?TF+j LF[ wFj\FOdIFJnC&gF@_=.GVDG>z}?G3X<D(MGsYOGaOGXWk]GschVG}G4 :H"qn(H81HW`?H&~!8mHzyH"HndsH[z1JH0HGvX.Hn?4II,jIB _CCJ9PkI0MJDQDTJYJO$~JeJ ZKn/h5KeBK->KCC\K([t/aKZcbK} K%K0HGv4sLVL}q^dLOe%sLC?LkZL,jInL}*LB*?MB _NFMh3)PMxp;RMghM-^M9pw nMR}(NPNK{-3IfN7y!8hxNpnNeNA`f{2OHpl zCOWOH& #vOOC(R$hO`:O&gF"kON P%UeKNX3U0FU"?9GUjOoeRU%jwUA?|6U2AU6g(iUmu`&U}*L@:V\A) "V7;V=W !fWtg 2mW?L*KX|3>%XfIfN9gTy?.g Bg'(? fg\1a;YgsHpg^?Gg gs2Pgha_LhcG:h$)hNXhCCJ!rhU=hmh ->i5livqi, jG%hWjcbKY?Bja)vZIiJj9MRMjIQ&0@Zj(<{8~jT,!HjlDr%P6jG%h%jjjsjE [.,Fk4l9Pk)sIjkX.Z,T|kh*Cxkkm5)jkYdk{ yzkHpl"/|lDQml6U4l=>m\dy/HmRE,Um.,FkTm[ wFhjmSnm=>mSm Un+j  RnIFpnzLW:nOiwVok| o9M $oo(/ 8|o_o"U6oLooJ[!)p,;s5pzo~kz#'>1zq4p${QYH{(<{B _S(|A`A?|R>kM|9M4pQ|*hE|; |!:9%} :H}^1w_U}DQ9~9w T!/~J5k~DQsXjm~~s_m|~C_~Qs~ha_o~j\tn X-n* 7k8iaW9 #9sDOpP[1`6S^"S')/08 :FIZY\`p\46CF^O_fjkblHx~} 4!!'4C:;_xdfWk%v5k-"59GvHK&\Rh{xx GD%l,22x44 ?OX]k~vyy~~e"=$R+-zM0UY*bbudgkqQ{ C Z k#m'm)h/2937GGY`Mbvbcme,%)K*k*B<S>_HQLSSjmtqvrs b !  y r" %' D( - @2 x5 ?C `\ n a|  V  1  4 ; uB G Q 6X Y ^ f qr t } -! ) Y* * 8 K M O U GV &[ k] ` n r W{ b{ )   l  M b! / 2 4 lI I V k] h n r u pw ~   " 3" j% % X7 < ^B C CT QU \ \ S\ f {  !@DSTT]VZv]d~i#j`suvv{21 v"&'>.589==@EMN/Z ^^argxy)w&.%IX__{bk, ; H j +OaJ"t&!./`4BBGTMSNVyX]h^befiBry5c=b(*+h-147=? BHWIVZb\lnx y "/'9+2//6Z@i@SGLQTJV0akmiqFsdw  ) <OP0RT^mr H q!$.1@3:BbCGwQI^b/cxcj?opEr|8d I<{Wcq}$N '../*55`@R [`rItyy7  $*4>A?KKgOWMo+(+ ,;pDD`MQ_be fm5k$v%*-012"4M4DJNKoUr8'4/:['g=l qzz9  r!#/./7{8bBBE HHN5a9bBuu%y B AERZN_Coqs ?Pu"-/:07d< GHbHvQw<3"&>}K)_Az{i  V # ( , +. WA E tM UU i m !K!5(!y-!s&h{&'4'M '#''M-'">'?'D'Z'_' p'u'mv'y'y'-z'}'(; (s(0((!(;8(<(@(Q(^(f(1){&)1)O2)`8)F)I)T)(_) d)@k)s)Q|)~)J** ****&*)*5*6*X:*<*%H*YK*L*L*`*e*h*=t*++(=+~J+sT+_+c+f+h+h+z+ ,H , ,,P',?,tV,Y],_,ie,pj,tj,no,x,{,|, -5 --G -#-$-&-*-$7-J-Ls-O ...$.7.S;.<.A.NH.Q.]R.R.FU. V.jk.zl.z/P%/(/./{S/f/i/j/k/m/00h0'070A0>H0`0.b07f0k0k0p0Ry0y~0K111 1181))1:1;1YD1mQ1TV1?^1a1e1g1g1 h1eq172|2Y2*22-"2,2a0272I2J2P2 S2V2iZ2$_2m2o2Vp2lr2Pv2}2 3w3 3U%353J3W35_3)m3r3q|3454-4C4+N49`4h4k4*l4-l4u4W{4n{44Z55j5(5_55J:5DH5T5]5Fc5jd5 i5=66 666%6!656=6`V6Y6@]6^6Pi6Xm6p6Zs6;7+7(7*7-47C7\7{i71k7{748 8y!8+8-8;8u@8[8C]8b8p{8{89U9`9I!9h#9)9)919Y79B9SG9K9O96P9[9Y\9|i9[:1 :! :$: (:e.:=:A:DE:JM:LY:x]:L`:,e:f:m:p:q:r::;;;^;;;;-,;72;2;4;6;mA;C;G;P;rb;d;g;ci;j;l;w;<1<<*<+< 6<F<U<Y<Z<b<1b<p<[}<}<(=(=-=.===nJ=]=^=o=d >p >>>>=!>u%>|&>(> 2>?>oG>{I>K>}M>=[>]>f_>u>x>z>{>?k ????r?`*?x;?vB?#K?RM?V?Y?j@3@!*@/@9@B@ E@G@*T@RU@r@?y@|@TA A\A#A#A'A1A05AU6AODO#KO#OOROWOdOpOJrOtO zOtPmPP=PPPtP P"PI=P(^Ps`P\cPdPdP3vPvP~PQg QQ,Q5Q7QIQ#LQdPQTQ8XQ_QsQzQARR R- Rv(R+Rj,R,R!.R71R+5R7R 9R,MR`RAcRVsRS<S# S$S ,S,S/S6S"FSHSNSfS T@TT!Tc1T;4TBTHTKTQT7RTUTUT `TaTnT3vT}T5UjU0U"U(U4OUKPU^UAaUU{U\|U,V'V'V.V5VCVCQV`V0pV}VVPWW WWOW%WU.W4W8W ?WAWRWVWWWKXX!X#X+XG4X@XDDXXXPbXiXlXuXvXY3 Y(Y(*Y+Y65Y8YFYNYgY@hYHYvZZZ*"Z%Z)Z,Z=ZKZ>XZ>tZuZyZ~Z[ [[#[t$[D[Q[Q[BY[x[ \ \2'\+\J<\w<\ =\7>\bB\O\uP\w\|\]a ] ]]]*]a2]2]e3];;]0Q]U]V].b]xi]ou]_]^)^ ^y ^"^3%^(.^Z2^@^[^?a^]c^c^m^Su^cz^|^6_9_ _!_"_c(_>_B_&Z_kb_c_'m_n_t_,}_`F``*`4`:`(;`=`3?`E`I`nK`K`AR`}`aa_*a`+au3a 9alAaFa/UaVa[ahahajaxabb /b13bJbFTbYb`bmbrb|b9}b ccc{.c/c6ccDcFcOHcddd ddi.d/d2dx3d?dmGd\ded~ddeeeeee@"e%eZ1eZ5e =eHCeFeTe_eheuef$f fZ fLfff%fV*f$1fV4fBfDfFf|]f4kfpf gg*g.g.g0gNgZgog&qg& h hh1h\h$h4h?hDh4GhYh[hY[h{h0|hiii% i> i %i1i1iiIi2diiiakioiwi_xi{iijUj j.j2j6jDjKj^j{lj~ljpjvjkk#k-kw5k@kBkLkWkw{k{k ldll#ll(l/l"2lC6lIlMlWlWlglllWnl mmm%m+m4m$:m@m^mJbm[qmsmNumn?n)nn!n?+n.n6/n4n?nNHnOnsenxnooo"ol#oI+o9o>oGonPo+dohonouoy~okp pp"p$p%p'p/p5p0;pq2?qLqWq\qbqfq~qq|rzr]rrrr rS.r5rpCr)crrrHyr|rr[ss s@sss's's-su8s9sb=sBsIsJs+TsTs]Xs_sdseshs isHjst tt't-t1ta2t:tDtGtEKtLtLt+\t\t/`tgt%ntumu'u,u'/u7=u=uGuIuJuQuRuZugaulu"zu}uzvvv vvv"vG)v{)v*v>EvFvJv,LvLv QvMRv`vevkfvgvmvtvwuw!w&w-w-w-w4w6w9w3Cw,UwoVw]w2gw@gwjwkwow|wxx-x;xe x!x*x.x}/xm8x9x`txitx|yywyT0y0y4y5y 9yAyEyFyIyLyXy?[y)\y*\yby2uy6|y z2z zFzz%z&z.z/z1zJEzOzTz(_zVdzSeziz{<{{{{4{8{9>{?{,R{h{n{o{q{r{|{Y~{o || |F|>|WA|D|*G|8S|w|f }o}4}7}=}L}S}/f}/n}w}z}]~}~w~;~~B)~1~;9~^>~}?~?~a@~E~DE~E~[~n~s~w~$N ]  "4=@wP`8lvzw; +/]36{OBSTert~Z cO'ERhVY_bdcnx|m\ak/!o%,?HJ O(Z&cccpp6yh%*]8s>>L_qkl G!9EpGxGN:Q1\c3gpruj #'5@,Ut\Cf}qv%w{k|R"b&.+3;/YlZ`eoq\s2z}3  N$,3M|awZx{g * @ !<;?;;>mC+HIIROSCkzmz$}%K'P(;?>~>qE`dhiq '$+1\>VN]_[g\h6r(t}tlw|'rk12:G;<>AfCOR,efnuOJs )*).TZ]mah Ol(#98E]S*`}g%L&))/58;;b<<GY'[Tl$oo(xpywy{,A'(C+J.QQQk. ( 3"HIJ7P4npq~| +n"$-Q71PBSwT6U"W_k}opu3|*G!!BwCTYaqAsy 24*9|?@VCS\_uv" izQ%6P=UG;JKf%m0nqe2T#/) *.;f?JK-XY|Z)[~\XbAcNdUy/lF6#!0d4C7!TsTWHa1dLeGox|*0n99G@O [Iqzqv ww|%}LR\`CHzKXpa)d!efiq!!(>yDHgLM|WXZ[bdl%pqvr s$H237?[N5_o~~(AJKQS0[/ccev'(+#-g6j>>rEJ)RRS|V[imogrhz| y#G+1@89:;BGnL'NRRTW[hklm'o[pwy pWI+9>?G#IKNVRWb``ow!{ c)/[>`llx8djS +4W/^'`L` nvxx{+J3yV\V^`Pcnqs6~uSo! $.17@.Z\c)f1fQuZw xj|z~K .O/[/1:=~CCFRl[n|~5 ^"C&~)*2<XBXCRWgZ`acg1hhv:w||1M[SU)\]bhln 489EI NzQ\TuVcmhtuyN x!K",2?@OAA}C.R{S)^e%gu8_ Oq(}2HLNOgPTkkz|_D #0(%|,I/9 OO[~~4*-(Z0;ILFKLPP/WBYZ`b f iv,yK  %i.<Y>/?r A$&(,*e--a3M8ABDOT^gq r HzMQ_!b5lr 7 2%(3Sb`ehuv %3X7ADL VVlWE[bm= C"(+)*9ADL-W\_k=k c+-5)8{>|AGN PS?gtyJ [!&('y()j.>3 8H5[b[e\kl 5@;E\FNpsgx T)67:AMQW``rr| #S/ < @CKNQkEpiqsta &`,Y-/ 4; CTK^NPQj\ho(wExgx( r#Ub~~| s#,.|/*505x6&= ?BKNLLn=oq ss#9(*-4CEMN Zizjxtnz{{#]Z %&;EBDHSV2WjoB}qaA "67979: <?>AoDHXZWesY{| 5O#'(2F>IKKMQ_`&a\y[S ( !!7;;<GEN[gzr~ w.w #EL9RTY[l__irttuy{/().n1<s]adgpl n#BuINQPR[ckgkrr) Of)o*:!?EELTUnXYKguz%(+k6)<PR$V@YcVyGXq X 6889x@ZQ[,\pqw\g-z/>GHIMyRdefilopyq &%J&&8;A`6f %w,8/@GJZzb|ffbruui~hbV&:;>??AWL`N gdhYkluozm DH!o%),/3:aFyF[VX6[r]}hj) A ILcS(U'VYpxj ' EEINXxEKM!&'-x/;HY]diIopv^ o"W)a?WASINCP|STU`|B}6Y#+2;b<JMbjpqE@ z!,41InX1\q~) < `pd3o677g8 @7LLMNUX\oh i Y 'EJGbbw ) ,^-.;/?JHNN\`yde&&4r7[>!?cK[e{i|$z $%()o/ 6e= ABIQCUdwY 1$&&e'4:?X_x}k %;?AsF&MWritQv}K'356BJ]JjSUWY\o}o0z079=XNFOX`ij%m8z50$$ $.2CWiahkWy|z {68j82EGMUDXZZbrD< &94f5x7FU`kn!4]a"cduegm{e,L(.r00T3o6?EGKMfMMPRR`em@u24F8GSTV^csmt^4#,59B+E^`h8kx(y]|#n&++QAIRp`d3hxrds81 P1'7+<<CAHIKQ\fl8r~   $$+5eDLck48A'J$P=RTYj rB &P(-IfX`ijmk@yy:} )r#-!2=>lJKw\\#]dorty"r \' )n0J}MNewx5+P EPXiYaAbLcPee[fw|"6n+6N;IBDqP^Uv_ov.P)n5<;A#Y&`cgj9rK ~:,i $t,.FLbllN )" +:183CMNw|oo@ Zx0@Unknown G.[x Times New Roman5Symbol3. .[x Arial9Garamond?. x@Arial Black7$BCambria5. .[`)TahomaC.,.{$ Calibri Light7..{$ Calibri;Wingdings?= .Cx Courier NewA$BCambria Math"1hha|'g{b ^ 9^ 9z4hoho 3qHP?2 ! xx^f joek Brian Marckx|                       Oh+'0p   , 8 DPX`hjoekNormalBrian Marckx228Microsoft Office Word@z7@:>@ccA@u` ^ ՜.+,D՜.+,D hp  Zacks Investment Research9ho  Title 8@ _PID_HLINKSA bzhttps://go.cms.gov/2L3cAgEOhttp://www.zacks.com/  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\^_`abcdfghijklstwRoot Entry F``v@Data |_1TableC WordDocument MSummaryInformation(]DocumentSummaryInformation8eMsoDataStore(s``W0UJEWBESSOCFQ==2(s``Item  2PropertiesUCompObj r   F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q